# EDGAR Filing Document

**Accession Number:** 0001593184
**File Stem:** 0001683168-25-006157
**Filing Date:** 2025-8
**Character Count:** 161981
**Document Hash:** 31e3a97ae86e3dd361d958f9b2234192
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-006157.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001683168-25-006157

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 66

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOREGENX, INC.
- **CENTRAL INDEX KEY:** 0001593184
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 462836541
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56345
- **FILM NUMBER:** 251218255

**BUSINESS ADDRESS:**
- **STREET 1:** 7407 ZIEGLER ROAD
- **CITY:** CHATTANOOGA
- **STATE:** TN
- **ZIP:** 37421
- **BUSINESS PHONE:** (866) 770-4067

**MAIL ADDRESS:**
- **STREET 1:** 7407 ZIEGLER ROAD
- **CITY:** CHATTANOOGA
- **STATE:** TN
- **ZIP:** 37421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FINDIT, INC.
- **DATE OF NAME CHANGE:** 20210219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARTEMIS ENERGY HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20131127

?xml version='1.0' encoding='ASCII'? BIOREGENX, INC. Form 10-Q

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 000-56345

BIOREGENX, INC.

(Exact name of Company in its charter)

<u>Nevada</u> <u>30-1912453</u> <br> (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification)

<u>7407 Ziegler Road</u>

<u>Chattanooga, TN 37421</u>

(Address of principal executive offices, including zip code)

Registrant's Telephone number, including area code: (866) 770-4067

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.406 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date. **The number of shares outstanding of the registrant's only class of common stock, as of August 13, 2025 was 961,156,152 shares of its $0.001 par value common stock.**

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION**

*This report contains statements reflecting our views about our future performance that constitute "forward-looking statements". Statements that constitute forward-looking statements are generally identified through the inclusion of words such as "aim," "anticipate," "expect," "intend," "may," "will" or similar statements or variations of such words and other similar expressions. All statements addressing our future operating performance, and statements addressing events and developments that we expect or anticipate will occur in the future, are forward-looking statements. These forward-looking statements are based on currently available information, operating plans and projections about future events and trends. They inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in any such forward-looking statement. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.* 

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**BIOREGENX, INC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **As of**<br> **June 30, 2025** | **As of**<br> **December 31, 2024** |
|  | **(Unaudited)** | |
| **<u>ASSETS</u>** |  |  |
| Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $46456 | $58404 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 21115 | 14992 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 134228 | 111094 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 47774 | 123306 |
| &nbsp;&nbsp;&nbsp;Total current assets | 249573 | 307796 |
| Property and equipment, net | 175985 | 200739 |
| Intangible assets, net | 725000 | – |
| **TOTAL ASSETS** | $1150558 | $508535 |
| **<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>** |  |  |
| Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $568799 | $427478 |
| &nbsp;&nbsp;&nbsp;Accounts payable - related parties | 332373 | 221788 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 405495 | 452960 |
| &nbsp;&nbsp;&nbsp;Accrued interest - related party | 495676 | 424277 |
| &nbsp;&nbsp;&nbsp;Notes payable and loans (including $522,500 in default) | 970117 | 883271 |
| &nbsp;&nbsp;&nbsp;Notes payable and loans - related parties | 1027885 | 1026387 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 125174 | 197027 |
| Total current liabilities | 3925519 | 3633188 |
| Royalty Liability | 700000 |  |
| Notes payable and loans, net of current | 179747 | 254606 |
| **TOTAL LIABILITIES** | 4805266 | 3887794 |
| Stockholders' Deficit: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001par value; 1,500,000,000 shares authorized; 961,156,152 issued and outstanding as of June 30, 2025 and 956,994,100 as of December 31, 2024 | 961156 | 956994 |
| &nbsp;&nbsp;&nbsp;Series A preferred stock, non-dividend, 2,500 votes per share, $0.001 par value, 50,000,000 authorized; issued and outstanding 3,800 shares | 4 | 4 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 31408548 | 30965084 |
| &nbsp;&nbsp;&nbsp;Common stock issuable, 1,936,000 shares at December 31, 2024 |  | 268620 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (36017194) | (35571995) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (7222) | 2034 |
| **TOTAL STOCKHOLDERS' DEFICIT** | (3654708) | (3379259) |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $1150558 | $508535 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements

**BIOREGENX, INC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gross sales | $446784 | $857534 | $963274 | $1542483 |
| &nbsp;&nbsp;&nbsp;Returns (including common stock and warrants issued for refunds of $41,511 in the period ended June 30, 2024) | (814) | (123502) | (2158) | (258903) |
| &nbsp;&nbsp;&nbsp;Net sales | 445970 | 734032 | 961116 | 1283580 |
| &nbsp;&nbsp;&nbsp;Cost of sales | 93514 | 264154 | 202630 | 429544 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 352456 | 469878 | 758486 | 854036 |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Distributors incentives | 2987 | 112588 | 11265 | 167246 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative (including equity compensation granted to officers, directors and contractors of $173,106 in the period ended June 30, 2025 and $2,512,706 in the period ended June 30, 2024) | 456728 | 1397087 | 1047095 | 4806023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 459715 | 1509675 | 1058360 | 4973269 |
| **Loss from operations** | (107259) | (1039797) | (299874) | (4119233) |
| **Other expense:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense and financing costs (Including related party interest of $35,455 in the six months ended in June 30, 2025 and $31,063 in June 30, 2024. | (71086) | (66331) | (145325) | (139353) |
| **Net loss** | $(178345) | $(1106128) | $(445199) | $(4258586) |
| **Weighted average common shares outstanding - basic and diluted** | 959205422 | 956530100 | 957743493 | 956530100 |
| **Loss per share - basic and diluted** | (0.00) | (0.00) | (0.00) | (0.00) |
| **Comprehensive Income:** |  |  |  |  |
| Net Loss | $(178345) | $(1106128) | $(445199) | $(4258586) |
| **Other comprehensive income (loss)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (7197) | 518 | (9256) | 1560 |
| **Other comprehensive loss** | $(185542) | $(1105610) | $(454455) | $(4257026) |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

**BIOREGENX, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(unaudited)**

For the six months ended June 30, 2024

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated Other Comprehensive**<br>**Income** | **Total Stockholders' Equity**<br>**(Deficit)** |
| **Balance, December 31, 2023** | 770833296 | $770833 | 3800 | $4 | $9676656 | $(12517978) | $(942) | $(2071427) |
| &nbsp;&nbsp;Issuance of common shares for services | 4040000 | 4040 |  |  | 685529 |  |  | 689569 |
| &nbsp;&nbsp;Fair value of options issued to officers and directors for services |  |  |  |  | 1823136 |  |  | 1823136 |
| &nbsp;&nbsp;Fair value of common shares and warrants issued for refunds | 160000 | 160 |  |  | 41391 |  |  | 41551 |
| &nbsp;&nbsp;Issuance of common shares as loan incentive | 144000 | 144 |  |  | 20695 |  |  | 20839 |
| &nbsp;&nbsp;Issuance of common shares to acquire technology | 76800000 | 76800 |  |  | 10579200 |  |  | 10656000 |
| &nbsp;&nbsp;Shares issued (retained) by Findit Inc's shareholders in merger with Findit, Inc. | 104552804 | 104553 |  |  | 7214041 |  |  | 7318594 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  | (4258586) |  | (4258586) |
| &nbsp;&nbsp;Other Comprehensive income | – | – | – | – | – | – | 1560 | 1560 |
| **Balance, June 30, 2024** | 956530100 | $956530 | 3800 | $4 | $30040648 | $(16776564) | $618 | $14221236 |

---

For the six months ended June 30, 2025

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | **Issuable Stock** | **Issuable Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated Other Comprehensive**<br>**Income** | **Total Stockholders'**<br>**Deficit** |
| **Balance, December 31, 2024** | 956994100 | $956994 | 3800 | $4 | 1936000 | $268620 | $30965084 | $(35571995) | $2034 | $(3379259) |
| &nbsp;&nbsp;Issuance and vesting of common shares for services | 1936000 | 1936 |  |  | (1936000) | (268620) | 401740 |  |  | 135056 |
| &nbsp;&nbsp;Issuance of common shares to directors | 571430 | 572 |  |  |  |  | 10601 |  |  | 11173 |
| &nbsp;&nbsp;Issuance of common shares as loan incentive | 500000 | 500 |  |  |  |  | 5400 |  |  | 5900 |
| &nbsp;&nbsp;Issuance of common shares for services | 1154622 | 1154 |  |  |  |  | 25723 |  |  | 26877 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  |  |  | (445199) |  | (445199) |
| &nbsp;&nbsp;Other Comprehensive loss | – | – | – | – | – | – | – | – | (9256) | (9256) |
| **Balance, June 30, 2025** | 961156152 | $961156 | 3800 | $4 | $– | $– | $31408548 | $(36017194) | $(7222) | $(3654708) |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

**BIOREGENX, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(unaudited)**

For the three months ended June 30, 2024

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated Other Comprehensive**<br>**Income** | **Total Stockholders' Equity**<br>**(Deficit)** |
| **Balance, April 1, 2024** | 956530100 | $956530 | 3800 | $4 | $29799102 | $(15670436) | $99 | $15085299 |
| &nbsp;&nbsp;Issuance of common shares for services |  |  |  |  | 67833 |  |  | 67833 |
| &nbsp;&nbsp;Fair value of options issued to officers and directors for services |  |  |  |  | 172854 |  |  | 172854 |
| &nbsp;&nbsp;Issuance of common shares as loan incentive |  |  |  |  | 859 |  |  | 859 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  | (1106128) |  | (1106128) |
| &nbsp;&nbsp;Other Comprehensive income | – | – | – | – | – | – | 519 | 519 |
| **Balance, June 30, 2024** | 956530100 | $956530 | 3800 | $4 | $30040648 | $(16776564) | $618 | $14221236 |

---

For the three months ended June 30, 2025

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated Other Comprehensive**<br>**Income** | **Total Stockholders'**<br>**Deficit** |
| **Balance, April 1, 2025** | 960292958 | $960293 | 3800 | $4 | $31319653 | $(35838849) | $(25) | $(3558924) |
| &nbsp;&nbsp;Issuance and vesting of common shares for services | 577479 | 577 |  |  | 83751 |  |  | 84328 |
| &nbsp;&nbsp;Issuance of common shares to directors | 285715 | 286 |  |  | 5144 |  |  | 5430 |
| &nbsp;&nbsp;Net loss |  |  |  |  |  | (178345) |  | (178345) |
| &nbsp;&nbsp;Other Comprehensive loss | – | – | – | – | – | – | (7197) | (7197) |
| **Balance, June 30, 2025** | 961156152 | $961156 | 3800 | $4 | $31408548 | $(36017194) | $(7222) | $(3654708) |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

**BIOREGENX, INC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| **OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(445199) | $(4258586) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 49754 | 1070261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discounts | 319 | 24801 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of options issued to officers and directors for services |  | 1823136 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common shares issued for services | 173106 | 689569 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common shares issued as loan incentives | 5900 | 19351 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest capitalized to debt balance | 6759 |  |
| &nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (6123) | 93638 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (23136) | 73605 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 75533 | 91337 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 141321 | 190115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable - related parties | 110585 | (16999) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (47465) | (5167) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest - related parties | 71399 | 59413 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Revenue | (71853) | (136065) |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 40900 | (281591) |
| **INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment |  | (189390) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of Intangibles | (50000) | (2652) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash acquired in DocSun transaction | – | 1445 |
| &nbsp;&nbsp;&nbsp;Net cash used in investing activities | (50000) | (190597) |
| **FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note and loan payments | (23592) | (29458) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in note and loan balances | 30000 | 400000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in note and loan balances - related parties | – | 32079 |
| &nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 6408 | 402621 |
| **NET EFFECT OF EXCHANGE RATE FLUCTUATIONS** | (9256) | 1560 |
| **NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS** | (11948) | (68007) |
| **CASH AND CASH EQUIVALENTS, BEGINNING BALANCE** | 58404 | 125402 |
| **CASH AND CASH EQUIVALENTS, ENDING BALANCE** | $46456 | $57395 |
| **CASH PAID FOR:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest | $44012 | $36621 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $– | $– |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common stock issued for intangible property and equipment in the acquisition of DocSun Biomedical Holdings, Inc. | $– | $10656000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common stock issued upon acquisition of intangible property and goodwill in the merger with Findit, Inc. | $– | $7318594 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common stock and warrants issued for refunds offset to deferred revenue | $– | $22200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of common stock and warrants issued for loan fees offset to loan discounts | $– | $20839 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclass of deposits to intangibles | $– | $150000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt discount upon issuance of notes payable | $– | $30000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liability incurred upon acquisition of intangible | $700000 | $– |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIOREGENX, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

*Organization and Business*

The Company, BioRegenx, Inc., develops and manufactures medical test equipment and high quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel, to health professionals and research organizations.

On April 6, 2021 the Company's consolidated group was formed by the contribution of 100% of the equity interests of three companies, Microvascular Health Services, LLC, My Body Rx, LLC and NuLife Sciences, Inc. in exchange for newly issued common and preferred stock representing all the issued and outstanding shares of BioRegenx. The combination is expected to product synergies between companies with the production activities and the distribution network of the marketing company.

On January 8, 2024, the Company acquired all the shares outstanding of DocSun Biomedical Holdings, Inc. in exchange for shares of the Company's stock. This acquired company is accounted for as an asset acquisition and the activities of the acquired company are included in the consolidated financial statements starting with the acquisition. Assets and liabilities are reported at the purchase price allocated to the relative fair market value.

The Company filed Articles of Merger effective March 8, 2024 with the state of Nevada. Pursuant to the Articles of Merger, BioRegenx, Inc, a Nevada corporation was merged into the Registrant (Findit, Inc), with the Registrant being the surviving company.

Pursuant to the merger, all of the issued and outstanding BioRegenx, Inc., a Nevada corporation, common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant. Concurrently, holder(s) of the Registrant's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The Series A and Series B preferred shares represented a voting control of 98.47% of the Registrant. Simultaneously, the majority shareholders retired a total of 172,197,602 common shares. As a result of the merger, the former shareholders of Findit retained 104,552,804 shares of common stock. The exchange value of Registrant's stock that was retained was valued at $7,318,594, based on the trading price of Registrant as of the date of the Merger. Due to the change in control the accounting acquirer in the merger is BioRegenx, Inc., a Nevada Corporation the Financial Accounting Standards Board's Accounting Standard Codification (ASC) Topic 805. This acquired company (Registrant) is accounted for as an acquisition and the activities of the acquired company are included in the consolidated financial statements starting with the acquisition. Assets are liabilities are reported at the purchase price allocated to the relative fair market value. The financial information reported before the merger date is that of the accounting acquirer, with adjustments to capital accounts and share amounts to reflect the surviving company's legal capital structure. The name of the Registrant was changed to BioRegenx, Inc. (the "Company").

Commensurate with the Merger, the Company effected a 16 for 1 split of its common shares. All share and per share amounts have been retro actively restated as if the reverse occurred as of the earliest period presented.

The Consolidated Financial Statements (the "Financial Statements") include the accounts and operations of the Company, and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The accounting and reporting policies of the Company conform with accounting principles generally accepted in the United States of America ("US GAAP").

*Basis of Presentation of Unaudited Financial Information*

The unaudited condensed consolidated financial statements of the Company for the three and six months ended June 30, 2025 and 2024 have been prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP") for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K for scaled disclosures for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of the management, necessary for the fair presentation of the Company's financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for the full fiscal year.

*Going Concern*

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates the continuation of the Company as a going concern.

The Company has generated recurring losses from operations and cash flow deficits from its operations since inception and has had to raise funds through equity offerings or borrowings to continue operating. These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the six months ended June 30, 2025, the Company incurred a net loss of $445,199 and had a Stockholders' deficit of $3,654,708 as of that date. At June 30, 2025, the Company had cash on hand in the amount of $46,456. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2024, has also expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern.

The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.

*Use of Estimates*

The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.

Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.

*Fair value of financial instruments*

The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. Accounting Standards Codification Section 820 defines the following levels of subjectivity associated with the inputs:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company's assumptions.

The carrying amounts of financial assets and liabilities, such as cash, accounts receivable, inventory, accounts payable, and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

*Revenue Recognition*

 

The Company applies ASC Topic 606, *Revenue from Contracts with Customers* ("ASC 606") for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:

1 – Identification of the contract with a customer

2 – Identification of the performance obligation in the contract

3 – Determination of the transaction price

4 – Allocation of the transaction price to the performance obligation in the contract

5 – Recognition of revenue when, or as, a performance obligation is satisfied

The Company through its subsidiaries provides a medical testing machine, consumables for the testing process, wellness devices and nutritional supplements The Company requires payment prior to shipping, with only a few exceptions. Sales are also not shipped until payment is received, typically via credit card. Shipping typically occurs in 24 hours of the payment. Sales are recorded. All product orders that are unused and returned within the first 30 days following purchase are refunded at 100% of the sales price.

*Other Revenue*

 

Other sales include fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and payment fees. Such fees are amortized over the period to which they relate, typically 12 months, which is recorded as other sales income.

*Disaggregation of Revenue*

 

Gross revenue received consisted of the following product sources:

---

| | | |
|:---|:---|:---|
| For the three months ended | 06/30/2025 | 6/30/2024 |
| &nbsp;&nbsp;&nbsp;Medical testing | $87116 | $338319 |
| &nbsp;&nbsp;&nbsp;Wellness devices | 5168 | 107961 |
| &nbsp;&nbsp;&nbsp;Nutritional | 354263 | 408815 |
| &nbsp;&nbsp;&nbsp;Other sales | 237 | 2439 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Sales | $446784 | $857534 |

---

---

| | | |
|:---|:---|:---|
| For the six months ended | 06/30/2025 | 6/30/2024 |
| &nbsp;&nbsp;&nbsp;Medical testing | $135649 | $498964 |
| &nbsp;&nbsp;&nbsp;Wellness devices | 5177 | 166348 |
| &nbsp;&nbsp;&nbsp;Nutritional | 821794 | 870055 |
| &nbsp;&nbsp;&nbsp;Other sales | 654 | 7116 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Sales | $963274 | $1542483 |

---

Gross revenue received consisted of the following customer types:

---

| | | |
|:---|:---|:---|
| For the three months ended | 06/30/2025 | 6/30/2024 |
| &nbsp;&nbsp;&nbsp;Medical and Academic | $181746 | $459962 |
| &nbsp;&nbsp;&nbsp;Customers and Direct Sales | 265038 | 397572 |
| &nbsp;&nbsp;&nbsp;Reseller | – | – |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Sales | $446784 | $857534 |

---

---

| | | |
|:---|:---|:---|
| For the six months ended | 06/30/2025 | 6/30/2024 |
| &nbsp;&nbsp;&nbsp;Medical and Academic | $349435 | $773511 |
| &nbsp;&nbsp;&nbsp;Customers and Direct Sales | 529912 | 706026 |
| &nbsp;&nbsp;&nbsp;Reseller | 83927 | 62946 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Sales | $963274 | $1542483 |

---

*Deferred Revenue*

The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially, filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied.

In 2024, the Company fulfilled its performance obligations for previously deferred shipments of wellness products and medical test machines, recognizing approximately $95,000 and $466,000 in revenue, respectively, for the year ended December 31, 2024. The revenue from medical test machines was reduced by $237,000, reflecting the fair value of equity instruments issued as refunds. Additionally, deferred revenue balance was reduced by approximately $22,000 due to the fair value of common stock issued for returns on items for which revenue had not been recognized (see Note 8). As of December 31, 2024, the Company's deferred revenue had a balance of $197,027, primarily consisting of $189,000 in customer advances for products not yet shipped. As of June 30, 2025, the Company had deferred revenue of $125,174, which was primarily related to funds received from customers in advance of shipment.

*Independent Business Partners Incentives*

Certain of the Company's products are distributed through a network of Independent Brand Partners (IBP). IBPs pay an annual membership fee to maintain the IBP status which is a requirement to participate in the compensation plan. IBP incentives expenses include all forms of commissions, and other incentives paid to our Independent Business Partners (IBPs). Commission expense and other amounts payable to IBPs are recorded upon recognition of sale.

*Selling, General and Administrative*

Selling, general and administrative expenses include wages and benefits, depreciation and amortization, rents and utilities, associate event costs, advertising and professional fees, marketing, and research and development expenses.

*Equity-Based Compensation*

The Company periodically issues stock options to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, *Compensation-Stock Compensation* whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

The fair value of each option or warrant grant is estimated using the Black-Scholes option-pricing model. The Company was previously a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies with characteristics similar to the Company. The expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

As of March 8<sup>th</sup>, 2024, the date of the merger, the Company's common shares were publicly traded on the OTC Markets Group exchange. On the date of merger and for subsequent transactions the fair values of equity instruments are determined with reference to the share price reported on the public exchange. For the period of January 1, 2024 through March 7, 2024, common shares of the Company were not publicly traded and the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company's judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms' length transactions, the rights and preferences of securities senior to the Company's common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each valuation date, as applicable.

*Advertising*

 

Advertising costs are charged to expense as incurred and are presented as part of the "Selling, general and administrative" line item. Advertising costs incurred during the three months ended June 30, 2025 and 2024 were $24,547 and $16,377, respectively Advertising costs incurred during the six months ended June 30, 2025 and 2024 were $45,567 and $28,079, respectively.

*Research and Development*

 

Research and development costs are expensed as incurred per ASC Topic 730. None of the activities of the Company in the periods presented qualified for exceptions to the general guidance of ASC Topic 730. Research and development costs incurred during the three-month ended June 30, 2025 and 2024 were $-0- and $7,500, respectively. Research and development costs incurred during the six months ended June 30, 2025 and 2024 were $-0- and $35,809, respectively.

*Net Income (Loss) per Share*

 

We calculate basic net income (loss) per share using the weighted average number of common stock shares outstanding during the period. For the calculation of diluted net income (loss) per share, we give effect to all the shares of common stock that were outstanding during the period plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is anti-dilutive. Dilutive potential shares of common stock consist of incremental shares of common stock issuable upon exercise of stock options and warrants.

For the six months ended June 30, 2025 and 2024 , there were no reconciling items related to either the numerator or denominator of the loss per share calculation, as their effect would have been anti-dilutive. Securities which may have affected the calculation of diluted earnings per share for the six months ended June 30, 2025 if their effect had been dilutive include 47,307,344 outstanding options and warrants to purchase our common stock and 1,936,000 unvested shares of common stock.

*Segments*

 

The Company operates in one segment for the manufacture and distribution of its products. In accordance with the "Segment Reporting" Topic of the ASC, the Company's chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under "Segment Reporting" due to their similar customer base and similarities in economic characteristics, nature of products and services, and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by "Segment Reporting" can be found in the accompanying financial statements.

*Recently Issued Accounting Standard*

In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

NOTE 2—INVENTORIES

Inventories, which consist of finished goods, are comprised of the following:

---

| | | |
|:---|:---|:---|
| Finished Goods: | **06/30/2025** | **12/31/2024** |
| Medical testing | $11260 | $23476 |
| Wellness devices | 30116 | 57144 |
| Nutritional | 92852 | 30474 |
| Total Finished Goods | $134228 | $111094 |

---

Medical testing equipment components were purchased and assembled once orders were received during the financial statement period. The medical testing components are salable separately in the form received. Nutritional inventories are purchased in finished form .

NOTE 3—PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

---

| | | |
|:---|:---|:---|
|  | 06/30/2025 | 12/31/2024 |
| Prepaid commissions | $5163 | $5163 |
| Other current assets | 42611 | 118143 |
| Total | $47774 | $123306 |

---

NOTE 4 – ACQUISITION OF DOCSUN TECHNOLOGY

On January 8th, 2024, the Company acquired 100% of the outstanding stock of DocSun Biomedical Holdings, Inc. ("DocSun") In exchange for 76,800,000 shares of Company stock valued at $10,656,000 and the application of $150,000 deposit that was paid in 2023. The total acquisition cost, including legal costs, amounted to $10,820,713. The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification ("ASC") 805. The assets acquired consisted of medical diagnostic technology with an estimated fair value of $10,773,000 that complements and expands the Company's product line and other assets with a value of $33,000.

The technology acquired from DocSun was being amortized based on an expected useful life of 5 years. During the year ended December 31, 2024, the Company amortized $2,107,960 of the capitalized cost resulting in a remaining unamortized balance of $8,665,108. Management performed its annual impairment test relating to the value of its Intangible assets as of December 31, 2024 and determined that it could no longer support it's carrying value, and as such, recorded an impairment charge of $8,665,108.

NOTE 5 – MERGER TRANSACTION WITH FINDIT

Effective March 8, 2024, BioRegenx, Inc, a Nevada corporation was merged into Findit, Inc., with Findit, inc. being the surviving company.

Pursuant to the merger, all of the issued and outstanding BioRegenx, Inc., a Nevada corporation, common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant. Concurrently, holder(s) of the Registrant's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The Series A and Series B preferred shares represented a voting control of 98.47% of the Registrant. Simultaneously, the majority shareholders retired a total of 172,197,602 common shares; as a result, the existing shareholder of Findit retained 104,552,804 shares of common stock valued at $7,318,594. Due to the change in control the accounting acquirer in the merger was determined to be BioRegenx, Inc., a Nevada Corporation in accordance with the Financial Accounting Standards Board's Accounting Standard Codification (ASC) Topic 805. This accounting acquire (Findit) is accounted for as an acquisition and the activities of the acquired company are included in the consolidated financial statements starting with the acquisition. Assets are liabilities are reported at the purchase price allocated to the relative fair market value. The financial information reported before the merger date is that of the accounting acquirer, with adjustments to capital accounts and share amounts to reflect the surviving company's legal capital structure. The name of the Registrant was changed from Findit, Inc. to BioRegenx, Inc.

The following table summarizes the fair value of the assets acquired and liabilities assumed on the date of acquisition, and as follows:

---

| | |
|:---|:---|
|  | **$ Amount** |
| Consideration |  |
| BioRegenx common stock &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 104,552,804 shares | $7318595 |
| Recognized amounts of identifiable assets acquired and liabilities assumed |  |
| &nbsp;&nbsp;&nbsp;Intangibles - search engine, domain, website, source code, provisional | $468553 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | (3037) |
| &nbsp;&nbsp;&nbsp;Accrued Interest | (27074) |
| &nbsp;&nbsp;&nbsp;Loan Payable | (225369) |
|  | 213073 |
| Goodwill, provisional | 7105522 |
| Total | $7318595 |
| Acquisition related costs | $80221 |

---

The technology acquired from Findit was being amortized based on an expected useful life of 5 years. During the year ended December 31, 2024, the Company amortized $76,000 of the capitalized cost resulting in a remaining unamortized balance of $392,000. Management performed its annual impairment test relating to the recorded value of its Goodwill and Intangibles relating to the acquisition of Findit and determined that it could not support the carrying value from current operations as of December 31, 2024, and as such, recorded an impairment charge of $7,497,998.

The proforma results of operations of Findit for the three and six month period ended June 30, 2024, were not material.

NOTE 6—INTANGIBLES

Identifiable intangible assets consisted of the following:

---

| | | |
|:---|:---|:---|
|  | 06/30/2025 | 12/31/2024 |
| Prepaid royalties | $750000 | $– |
| Less accumulated amortization | (25000) | – |
| Net intangible assets | $725000 | $– |

---

On May 5, 2025, the Company entered into a binding sub-license and purchase agreement with the owners of certain intangible technology and distribution license on which the GlycoCheck systems are based. The sub-license and royalty period applies retroactively to November of 2023. The agreement calls for a royalty of $500 for each GlycoCheck system sold. The contract calls for an unconditional minimum of $750,000 in royalties over the three-year sub-license term. The Company is amortizing the license agreement as the units are sold. The Company has recorded $25,000 in royalty expense related to the commitment in the three-months ending June 30, 2025.

See Notes 9 Commitments and Contingencies.

NOTE 7—ISSUANCE OF COMMON STOCK AND OPTIONS

*<u>Issuance of common stock for services</u>*

During the period ended March 31, 2024 the Company granted 7,912,000 shares of its common stock with a fair value of $1,097,790 to two consultants for services. One tranche of shares of stock issued had a vesting term of 50% at grant date, 25% on 1<sup>st</sup> year anniversary date, and the remaining 25% on 2<sup>nd</sup> year anniversary from grant date. During the periods ended June 30, 2025 and 2024 shares with a fair value of $135,056 and $621,736 vested and are included in Selling, General and administrative expenses. As of December 31, 2024, there were 1,936,000 unvested shares with a fair value of approximately $268,620 issuable. In February, 2025, the 1,936,000 shares issuable at December 31, 2024 were issued and recorded $135,056 for the unvested shares from previous grants. As of June 30, 2025, unamortized compensation of $270,859 will be recognized through December 31, 2025.

During the period ended June 30, 2025, the Company issued 1,154,622 common shares to consultants and professionals for services with an aggregate fair value of $26,877 which was recorded to general and administrative expenses.

During the period ended June 30, 2025 the Company granted 571,430 shares of its common stock with an aggregate fair value of $11,173 to its directors and an officer for services provided.

*<u>Issuance of common stock as loan incentives</u>*

In the six months ended June 30, 2024, the Company granted 144,000 shares of its common stock with a fair value of $20,839 to two note holders. The fair value of the shares issued were accounted for as loan fees. In the six months ended June 30, 2025, the Company granted 500,000 shares of its common stock with a fair value of $5,900 to two note holders as a loan fee.

*<u>Issuance of common stock and warrants for refunds</u>*

In November 2023, the Company offered to certain customers whose orders had been deferred, the option of accepting shares of common stock or warrants to acquire common stock, as compensation for the delivery delay. There were 2,080,000 shares with a fair value of $390,000 and 480,000 options with a fair value of $67,180 issued in 2023 under the offer. In January of 2024, there were 160,000 shares with a fair value of $22,200 and 160,000 options with a fair value of $19,351 issued under the offer. The offer was closed in January 2024. For accounting purposes, the Company recorded fair value of the shares and options issued during the period ended June 30, 2024 in the aggregate amount of $41,551, and reduced deferred revenue by $22,200 and returns reserves by $19,351 for the period ended June 30, 2024.

*<u>Stock option awards</u>*

During the period ended June 30, 2024 the Company granted options to acquire 23,575,328 shares of its common stock at $.13 per share with a fair value of $2,851,047 to two officers and directors. At grant date 853,328 of the options vested immediately, and 22,720,000 of the options had a vesting term of 50% at grant date, 25% on 1<sup>st</sup> year anniversary date, and the remaining 25% on 2<sup>nd</sup> year anniversary from grant date. During the period ended June 30, 2024, options with a fair value of $1,823,136 vested and are included in Selling, General and administrative expenses.

For stock options and warrants granted, the Company estimated the fair value of each stock option or warrant at grant dates using the Black-Scholes option-pricing model with the following assumptions:

---

| | |
|:---|:---|
|  | **2024** |
| Risk-free interest rate | 4.17% |
| Expected dividend yield | 0.00% |
| Expected volatility | 130% |
| Expected life | 4 yr |

---

A summary of all stock options and warrants outstanding as of June 30, 2025 follows:

---

| | | |
|:---|:---|:---|
|  | **Number of <br> Shares** | **Weighted-Average**<br> **Exercise Price** |
| Outstanding as of December 31, 2024 | 47292344 | $0.19 |
| Granted | 15000 | 0.20 |
| Exercised |  |  |
| Forfeited | – | – |
| Outstanding as of June 30, 2025 | 47307344 | $0.19 |
| Exercisable at June 30, 2025 | 35409338 | $0.18 |

---

Options and Warrants Outstanding and Exercisable at June 30, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Range of <br> Exercise Price** | **#of Options and Warrants Exercisable** | **Weighted Average <br> Exercise Price** | **Weighted Average Remaining (Years)** |
| $0.13 to 0.37 | 35409338 | $0.18 | 4.95 |

---

The outstanding and exercisable options and warrants had no intrinsic as on June 30, 2025.

NOTE 8—LOANS

The Company, through certain subsidiaries, financed past activities, in part, with borrowing from private parties, Small Business Administration's Economic Injury Disaster Loans (EIDL) and related parties. Loans from unrelated parties are as follows:

---

| | | |
|:---|:---|:---|
|  | 06/30/2025 | 12/31/2024 |
| (A) Howard note - In Default | $50000 | $50000 |
| (A) Howard note - In Default | 50000 | 50000 |
| (B) Goff note - In Default | 22500 | 22500 |
| (C) Insurance notes |  | 11128 |
| (D) Alder note, net of discount | 163267 | 163644 |
| (D) Genesis Glass note, net of discount | 152912 | 165000 |
| (E) EIDL notes ($400,000 in default) | 550000 | 550000 |
| (F) Other | 161805 | 126479 |
| Total | 1150484 | 1138751 |
| Less unamortized discount | (620) | (874) |
| Less current portion | (970117) | (883271) |
| Total long term | $179747 | $254606 |

---

(A) The first Howard note was advanced on 06/28/2016 and the second on 04/03/2017 to Microvascular Health Solutions, LLC. Both notes had one-year terms and both notes are in default. The stated interest rate on each note was 2.5% per month, upon default the interest rate increased to 3.5% per month. The notes are secured by the accounts receivable of the borrower. At year end after the default each note contained a provision entitling the lender to 5% ownership in the borrower, a consolidated subsidiary. The Company estimates that if the interest in the subsidiary were converted into its common shares it would represent an equivalent of 29,400,000 common shares, which would only be issuable in lieu of the interest in the subsidiary, if agreed upon by the Company.

(B) The Goff note had a maturity
 date of February
 13<sup>th</sup>, 2016 and is in default. The
 original note advanced $15,000 and called for a payment of $22,500 on the maturity date. The note provides for a 4% interest rate
 per annum after the maturity date.

(C) Insurance notes are from finance companies that provided short term financing of insurance premiums. The notes require ten installments and were paid off as of June 30, 2025.

---

| | |
|:---|:---|
| (D) | On January 10<sup>th</sup>, 2024, the Company issued two unsecured notes for $165,000 each, Alder and Genesis Glass. The notes are due in twelve months from the note date or before if the Company brings in equity equal to $1,500,000. The funds were designated for the improvement of the technical infrastructure of the newly acquired DocSun Biomedical Holdings, Inc. Each note was issued with a $15,000 original issue discount and the issuance of 72,000 common shares with a fair value of $9,990 were paid to each lender as an additional loan fee, resulting in an aggregate loan discount of $49,980 which was amortized over the initial life of the loan. Subsequent to year end the loans were extended until October 9<sup>th</sup>, 2025 by agreement with the lender. The extension terms call for 1% interest per month and $5,000 payments per month on the Genesis Glass note until May 2025 at which time the payments become $5,000 per month for each note. The Company had issue 250,000 common shares to the lender for each note extended. In the event of default, the Company will issue the lender 3,000,000 shares of its common stock and the monthly interest rate increases to 1.5%. |
| (E) | As of December 31, 2023, the Company had two outstanding economic injury disaster loans (EIDL loan) issued under the Small Business Administration's COVID-19 recovery program of $200,000 and $150,000. During 2024, the Company assumed another EIDL loan in the amount of $200,000 upon the acquisition of Findit, Inc. (see Note 5) resulting in total balance due as of June 30, 2025 and December 31, 2024 of $550,000. The EIDL loans are secured by the Company's assets. Each loan has a 30-year term and an interest rate of 3.75% per annum. The SBA granted a total of thirty months payment deferment period under the EIDL program for Covid-19 related loans, all of the EIDL loans qualified for and used the full deferment period. Interest continued to accrue during the deferment period and the deferred amounts will be paid as a balloon payment at the end of the 30-year amortization period. Current payments are being applied against interest accrued. The notes maturity dates are May 17, 2050 for a $150,000 note, July 12, 2051 for a $200,000 note and July 17, 2050 for the $200,000 Findit EIDL loan. |
|  | As of June 30, 2025, the Company was delinquent on payments on two of the EIDL loans in the aggregate amount of $400,000, and such amounts have been reflected as current in the accompanying financial statements. |
| (F) | As of June 30, 2025 and December 31, 2024, four and five notes including accrued interest in aggregate amounts of $181,436 and $140,621, respectively, were due. A total of 65,000 warrants with a fair value of $1,284 were issued in relation to the note proceeds and were recorded as a valuation discount to be amortized over the life of the note (of which $620 remains to be amortized at June 30, 2025). The convertible notes have a stated interest rate of 16%, of which 10% is payable by adding to the principal of the note and 6% is payable in cash, biannually. The notes are convertible into common shares at the option of the noteholder at 0.09 cents per common share. The notes mature 2 years after the note date. The Company has the option to convert the convertible notes in the event of an uplist to a national stock exchange. The conversion price to the Company is the lessor of 0.09 cents or 85% of the price at on the national exchange. For each $5,000 principal of the notes, the Company granted 2,500 warrants to purchase common stock at 0.20 cents per common share. The warrants expire 2 years after the Company's shares are listed on an internationally recognized exchange. The amounts recorded are net of unamortized discounts of $620 consisting of the fair value of the warrants granted. A total of $10,806 interest is included in the loan balances. |

---

*Related Party Loans*

BioRegenx and its subsidiaries have financed past activities, in part, with unsecured borrowings from certain related parties. Each of the listed loans below indicated with an A are demand loans that have a one-year term and an auto renewal feature. They bear interest rates from 8% to 16% per annum. The loan indicated with a B does not have stated terms. See note 10 for description of security.

The principal amount of debt from related parties is summarized in the following table:

---

| | | |
|:---|:---|:---|
| <u>Related Party</u> | 06/30/2025 | 12/31/2024 |
| Libertas Trust | 180000 | 180000 A |
| Wilshire Holding Trust | 518000 | 518000 A |
| Resco Enterprises Trust | 157747 | 157747 A |
| Avis Trust | 67606 | 67606 A |
| JS Bird | 32079 | 32079 A |
| Thomas Power | 32591 | 31093 A |
| Richard Long | 39862 | 39862 |
|  | 1027885 | 1026387 |

---

The entire balance of related party loans is recorded as current liabilities.

Total accrued interest on related party debts was $495,676 at June 30, 2025 and $424,277 at December 31, 2024.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

*Lease Commitments*

The Company leases office space for its headquarters in Chattanooga Tennessee on a short-term lease. The headquarters is leased from a related party on a month-to-month basis for $1,725 per month. In addition, the Company also rents storage space on a month-to-month basis in various locations total monthly cost was less than $1,000 per month.

*Warrants issuable upon financing*

In August 2023, Hitesh Juneja, a former employee, was granted warrants in an amount to be determined based on the amount of approved equity financing related to his efforts. The grant provided for warrants equal to ½% of the outstanding shares at the time of the grant. Warrants for the ½% of outstanding shares would be issued for bringing in $1,000,000 of equity, with a maximum percentage of 7% for larger equity fundings. The warrants would be exercisable at the fair market value of the shares on the date of funding. The warrants are exercisable one third on the date of grant and one third each of the next two years. No warrants have been issued under this grant and no compensation expense has been recognized.

*VHS Pool*

In January of 2025, a member of the VHS Pool contacted the Company and claimed the change in ownership of Microvascular Health Solutions when it became a subsidiary of the Company in April of 2021 may potentially constitute a liquidity event which would accelerate the VHS Pool payments. The Company and the VHS Pool Member have since been negotiating terms of a revised royalty agreement. The parties agreed to a tolling of the statute of limitations of the potential breech until the earlier of June 30, 2026 or within in 60 days should either party terminate the agreement. The Company does not believe there has been a breach and that the effect of a revised agreement will not have a material effect on the financial statements or future operations.

*GlycoCheck B.V. Lawsuit*

On April 21, 2025, former officers and directors of the Company, Bob Long and Hans Vink, in their capacity as directors of GlycoCheck B.V. ("GlycoCheck"), filed a complaint against the Company and its subsidiary, MicroVascular Health Solutions, LLC, in the Business and Chancery Court of the State of Utah, alleging breach of contract and related damages resulting from unpaid royalties and unjust enrichment. The plaintiffs are claiming damages in excess of $566,682. The Company has evaluated the claims and considers them to be without merit, based on the following reasons; (1) in November 2023, GlycoCheck lost its license to use the technology, which was the basis of the contract that is the subject of the claim, (2) the licensor of the technology is an unrelated party and has allowed the Company to continue to operate under the terms of the original agreement and (3) there were no amounts paid or accrued under the contract during the years ended December 31, 2024 and 2023.

The Company records a liability when a particular contingency is probable and estimable. While assurance cannot be given as to the outcome of these disputes, management does not currently believe that this matter is estimable or probable and is therefore unable to represent whether they would have a material adverse effect on the Company's financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future. See Note 6 – Intangibles.

*GlycoCheck Intangible Property Agreement*

On May 5, 2025, the Company entered into a binding sub-license and purchase agreement with the owners of certain intangible technology and distribution license on which the GlycoCheck systems are based. The sub-license and royalty period applies retroactively to November of 2023. The agreement calls for a royalty of $500 for each GlycoCheck system sold, and the funding of a prepaid royalty account within 60 days of the contract date. The contract calls for a minimum of $750,000 in royalties over a three-year sub-license term. The Company is obligated to exercise a purchase option to purchase the intangible property for $1,000,000, payable in common shares of the Company at a time of its choosing within the three-year sub-license term. As of the contract date the Company will receive all accounts receivables of the licensor which have negligible value and have been recorded as prepaid assets at $100. The Company is also obligated to reimburse the intangible property owners for patent renewals, including the last two years, representing approximately $37,000 in reimbursements of past costs. As of June 30, 2025 approximately $22,000 remains to be paid on prior renewal costs.

See Note 6 – Intangibles.

*Company disputes and other claims*

The Company is involved in other disputes, not disclosed individually, with certain parties, including parties that are former officers and board members and vendors associated with their activities. Such disputes arise from time to time in the ordinary course of conducting business. The disputes including matters involving amounts due to the Company, contract performance standards, and liabilities under contracts or arrangements entered by the prior officers including with parties related to them. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While assurance cannot be given as to the outcome of these disputes, management does not currently believe that any of these matters, individually or in the aggregate are estimable or probable and is therefore unable to represent whether they would have a material adverse effect on the Company's financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.

NOTE 10 — RELATED-PARTY TRANSACTIONS

*Rental*

The Company rents its home office from BBD Holdings, LLC which is controlled by Joseph Bird, an officer and director. The rental is on the month-to-month basis and is at a rate of $1,725 per month which is no more than the prevailing rate for the Chattanooga, TN market. Rent paid during the six months ended June 30, 2025 and 2024 were $10,350 and $10,350, respectively.

*Royalties*

The Company sells a product subject to a royalty agreement with the VHS Pool that was set up by a predecessor entity, through two if its subsidiaries. A former officer and director – Robert Long through a related entity – Lone Peak Innovative Holdings, LLC, has a creditor interest in the VHS Pool. Lone Peak Innovative Holdings, LLC has to date not received payments from the VHS Pool and the likelihood of future payments are not ascertainable.

The royalty agreement calls for the payment of 1% of the gross sales of the subject product(s). The royalty applies to any product designed to support a healthy Endothelium Glycocalyx, such as the Company's Endocalyx. The royalty agreement also calls for the payment of 1% of the proceeds, after taxes, on a liquidity event. A liquidity event is defined as the subsidiary entering an arms-length transaction with a third party or making an initial public offering. Should a liquidity even occur, the agreement requires a minimum payment to raise the pool amount to $7,500,000. The pool ceiling is $15,000,000 and the Company may have two subsidiaries subject to the agreement.

In January of 2025, a member of the VHS Pool contacted the Company and claimed the change in ownership of Microvascular Health Solutions when it became a subsidiary of the Company in April 0f 2021 may potentially constitute a liquidity event which would accelerate the VHS Pool payments. The Company and the VHS Pool Member have since been negotiating terms of a revised royalty agreement. The parties agreed to a tolling of the statute of limitations of the potential breech until the earlier of June 30, 2026 or within in 60 days should either party terminate the agreement. The Company does not believe there has been a breech and that the effect of a revised agreement will not have a material effect on the financial statements or future operations.

Royalties paid during the three months periods ended June 30, 2025 and 2024 were $4,181 and $2,562, respectively.

Royalties paid during the six months periods ended June 30, 2025 and 2024 were $6,898 and $5,536, respectively.

*Distribution Agreement*

The Company has a worldwide distribution agreement with GlycoCheck B.V. for the GlycoCheck machine distribution. Bob Long and Hans Vink were directors of BioRegenx, Inc. and are directors of Glycocheck B.V. and may have an ownership interest in Glycocheck B.V. Mr. Long and Mr. Vink have left the Company and have called into question the status of the distribution agreement by issuing a cancellation notice. There were no amounts paid or accrued under the distribution agreement during the three months ended June 30, 2025 and the year ended 2024. The cancellation notice was issued in January of 2024 without the consent of the majority owners of GlycoCheck B.V. In November 2023, GlycoCheck B.V. lost its license to use the technology, which was the basis of the distribution agreement with the Company. The licensor of the technology is an unrelated party and has allowed the Company to continue to operate under the terms of the original agreement. See Note 6 – Intangibles.

*Legal Counsel*

The Company's legal counselors included a former member of the board of directors, Jody Walker. Jody provided legal services for SEC reporting and general legal matters through her firm J.W. Walker & Associates until her resignation in July of 2024. The balance of $72,061 was still owed by the Company as of June 30, 2025. In January 2024, Jody was granted 6,880,000 option to acquire common stock at $0.13 per share. The options with a fair value of $832,092 were included in selling, general and administrative expenses. Legal fees paid during six-month periods ended June 30, 2025 and 2024 were $-0- and $-0-, respectively.

*Accounts Payable – Related Parties*

The Company reimburses certain officers and board members for company expenses paid through individual credit cards. Total short-term advances from Resides Enterprises, a company controlled by William Resides, Chief Executive Officer, were $253,921 at June 30, 2025, and $199,740 at December 31, 2024 and from Thomas Power were $51,250 at June 30, 2025, and $-0- at December 31, 2024. Balances due prior officers and board members were $27,202 at June 30, 2025 and $22,048 at December 31, 2024.

*Notes Payable – Related Parties*

Certain related party loans are secured by all assets of the Company or all assets of a subsidiary as evidenced by UCC Financing Statements as follows:

---

| | |
|:---|:---|
| Filed on Loans to BioRegenx |  |
| Libertas Trust | $180000 |
| Wilshire Holding Trust | $518000 |

---

---

| | |
|:---|:---|
| Filed on Loans to NuLife Sciences |  |
| Resco Enterprises Trust | $157747 |
| Avis Trust | $67606 |

---

NOTE 11—SEGMENT INFORMATION

The Company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. The Company focuses on commercialization of its patented technologies in its field.

The Company's Chief Operating Decision Maker (CODM) reviews financial information and presented and decides how to allocate resources based on potential new revenues. gross sales, cost of goods sold and net income (loss) are used for evaluating financial performance.

Significant segment items used by the CODM include gross sales, cost of goods sold, salaries, stock based compensation, distributor incentive, legal and accounting, depreciation and amortization and interest expense.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Schedule of segment reporting** | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Net Sales | 445970 | 734032 | 961116 | 1283580 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of Sales | 93514 | 264154 | 202630 | 429544 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Salaries and Wages | 117724 | 183408 | 215944 | 365402 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Based Compensation | 89758 | 240687 | 173106 | 2512705 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributors incentives | 2987 | 112588 | 11265 | 167246 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal and accounting | 115701 | 110335 | 265310 | 273003 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 12377 | 569731 | 49754 | 1095062 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating expenses | 121168 | 292926 | 342981 | 559851 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 71086 | 66331 | 145325 | 139353 |
| **Net loss** | $(178345) | $(1106128) | $(445199) | $(4258586) |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The Company was originally incorporated on December 23, 1998 in the state of Nevada as "Knowledge Networks, Inc." The Company's name was changed to "Findit, Inc." on March 25, 2016. On March 8, 2024, the Company was the surviving corporation in a merger transaction (described below), and, as part of the merger transaction, the Company's name was changed to "BioRegenx, Inc."

The Company develops and manufactures medical test equipment and high quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel, to health professionals and research organizations.

On April 6, 2021, the Company's consolidated group was formed by the contribution of 100% of the equity interests of three companies, Microvascular Health Services, LLC, My Body Rx, LLC and NuLife Sciences, Inc. in exchange for newly issued common and preferred stock representing all the issued and outstanding shares of the Company. The combination is expected to produce synergies between companies with the production activities and the distribution network of the marketing company.

On January 8, 2024, the Company acquired all the shares outstanding of DocSun Biomedical Holdings, Inc. in exchange for shares of the Company's stock. This acquired company is accounted for as an asset acquisition and the activities of the acquired assets are included in the consolidated financial statements starting with the acquisition.

Pursuant to Articles of Merger effective March 8, 2024, BioRegenx, Inc., also a Nevada corporation (the "merged entity"), was merged into the Company ("surviving entity")and the Company adopted and changed its name to the merged entity's name - "BioRegenx, Inc."

Pursuant to the merger, all of the issued and outstanding common and preferred shares of the merged entity were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Company. which represented 90.0% of the voting securities of the Company. Concurrently, holder(s) of the Company's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The Series A and Series B preferred shares represented a voting control of 98.47% of the Company. Simultaneously, the majority shareholders retired a total of 172,197,602 common shares. The Company's post-merger existing shareholders retained 104,552,804 shares of common stock. The exchange value of the publicly traded stock that was retained was valued at $7,318,594, based on the Company's trading price as of the date of the Merger.

The Company develops and manufactures medical test equipment and high quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel, to health professionals and research organizations.

<u>Results of Operations</u>

*The following discussion may contain forward-looking statements, and our actual results may differ materially from the results suggested by these forward-looking statements. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.*

 

*We are a smaller reporting company and have incurred substantial losses in connection with our operations. We will need substantial capital to fund working capital in order to pursue our current plans to develop our business.*

 

The tables presented below compare our results of operations for the three and six months ended June 30, 2025 to the three and six months ended June 30, 2024, in both dollars and percentages.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | | |
|  | **June 30, 2025** | **June 30, 2024** |<br>**$ Variance Favorable/ (Unfavorable)** |<br>**% Variance Favorable/ (Unfavorable)** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gross sales | $446784 | $857534 | $(410750) | -48% |
| &nbsp;&nbsp;&nbsp;Returns | (814) | (123502) | 122688 | 99% |
| &nbsp;&nbsp;&nbsp;Net sales | 445970 | 734032 | (288062) | -39% |
| &nbsp;&nbsp;&nbsp;Cost of sales | 93514 | 264154 | 170640 | 65% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 352456 | 469878 | (117422) | -25% |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Distributors incentives | 2987 | 112588 | 109601 | 97% |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 456728 | 1397087 | 940359 | 67% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 459715 | 1509675 | 1049961 | 70% |
| **Loss from operations** | (107259) | (1039797) | 932538 | 90% |
| &nbsp;&nbsp;&nbsp;Interest expense and financing costs | (71086) | (66330) | (4755) | -7% |
| **Net loss** | $(178345) | $(1106128) | $927783 | 84% |

---

For the three months ended June 30, 2025, the Company had gross sales of $446,784 and returns of $(814) resulting in net sales of $445,970. Comparatively, for the three months ended June 30, 2024, the Company had gross sales of $857,534 and returns of $(123,502) resulting in net sales of $734,032. Net sales decreased by 39% and returns decreased by 99% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024. The resulting decrease in net sales and returns related to the product issues experienced with the medical testing machine.

Cost of sales were $93,514 resulting in gross profit of $352,456 for the three months ended June 30, 2025. Cost of sales were $264,154 resulting in gross profit of $469,878 for the three months ended June 30, 2024. Cost of goods sold decreased by 65% and gross profit decreased by 25% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024. The resulting decrease related to lower product sales caused by the effects on the distributor base from product issues experienced with the medical testing machine.

For the three months ended June 30, 2025, the Company paid out distributors' incentives of $2,987 and other selling, general and administrative expenses of $456,728 resulting in total operating expenses of $459,715. These selling, general and administrative expenses consisted primarily of employee expenses of $124,513 and other operating expenses of $335,202. Other operating expenses consisted of advertising and marketing of $24,547, depreciation expense of $12,377, software costs of $2,178, bank and payment charges of $1,352, contract labor of $24,650, legal and accounting of $115,701, professional services of $48,921, which includes $89,759 of fair value of grants of common shares, insurance of $9,222, taxes and licenses of $1,346, rent & lease of $17,801 and miscellaneous expenses of $77,107. Additionally, the Company had interest expense and financial costs of $71,086 resulting in net loss of $(178,345) for the three months ended June 30, 2025.

Comparatively, for the three months ended June 30, 2024, the Company paid out distributors' incentives of $112,588 and had selling, general and administrative expenses of $1,397,087 resulting in total operating expenses of $1,509,675. These selling, general and administrative expenses consisted primarily of employee expenses of $332,863, amortization expense of $562,089 and operating expenses of $502,135. Operating expenses consisted of advertising and marketing of $16,377, software costs of $9,973, product development costs of $450, bank and payment charges of $18,273, contract labor of $55,578, legal and accounting of $110,335, professional services of $218,475, insurance of $20,868, taxes and licenses of $4,971, rent & lease of $11,537, travel of $4,723 and miscellaneous expenses of $30,575. Additionally, the Company had interest expense and financial costs of $66,331 resulting in net loss of $(1,106,128) for the three months ended June 30, 2024.

Distributor incentives decreased by 97% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 as a result of the reduction in sales between the periods. Selling, general and administrative expenses decreased by 70% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024, decreases relating to equity compensation granted and legal, accounting, professional and amortization cost during the three months ended June 30, 2025.

The Company had a loss from operations of $(107,259) and $(1,039,797) for the three months ended June 30, 2025 and June 30, 2024, respectively. For those same periods, the Company had interest expense and financing costs of $(71,086) and $(66,330). As a result, the Company had a net loss of $(178,345) and $(1,106,128) for the three ,months ended June 30, 2025 and June 30, 2024, respectively. Net loss decreased by 84% and interest expense increased by 7% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024. The resulting decreases related to decreases in net sales and in returns related to the product issues experienced with the medical testing machine and a resulting equity refund offer by the Company, equity compensation, legal, accounting, professional and amortization expenses. Interest expense increased due to higher debt balances during the three months ended June 30, 2025 compared to the three months ended June 30, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Six months Ended** | **For the Six months Ended** | | |
|  | **30-Jun-25** | **30-Jun-24** |<br>**$ Variance Favorable/ (Unfavorable)** |<br>**% Variance Favorable/ (Unfavorable)** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gross sales | $963274 | $1542483 | $(579209) | -38% |
| &nbsp;&nbsp;&nbsp;Returns | (2158) | (258903) | 256745 | 99% |
| &nbsp;&nbsp;&nbsp;Net sales | 961116 | 1283580 | (322464) | -25% |
| &nbsp;&nbsp;&nbsp;Cost of sales | 202630 | 429544 | 226914 | 53% |
| &nbsp;&nbsp;&nbsp;Gross profit | 758486 | 854036 | (95550) | -11% |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Distributors incentives | 11265 | 167246 | 155981 | 93% |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 1047095 | 4806023 | 3758928 | 78% |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 1058360 | 4973269 | 3914909 | 79% |
| **Loss from operations** | (299874) | (4119233) | 3819359 | 93% |
| &nbsp;&nbsp;&nbsp;Interest expense and financing costs | (145325) | (139353) | (5972) | -4% |
| &nbsp;&nbsp;&nbsp;Total other expenses | (145325) | (139353) | (5972) | -4% |
| **Net Loss** | $(445199) | $(4258586) | $3813387 | 90% |

---

For the six months ended June 30, 2025, the Company had gross sales of $963,274 and returns of $(2,158) resulting in net sales of $961,116. Comparatively, for the six months ended June 30, 2024, the Company had gross sales of $1,542,483 and returns of $(258,903) resulting in net sales of $1,283,580. Net sales decreased by 38% and returns decreased by 99% for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. The resulting decrease in net sales related to the product issues experienced with the medical testing machine and its effect on nutritional sales.

Cost of sales were $202,630 resulting in gross profit of $758,486 for the six months ended June 30, 2025. Cost of sales were $429,544 resulting in gross profit of $854,036 for the six months ended June 30, 2024. Cost of goods sold decreased by 53% and gross profit decreased by 11% for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. The resulting decrease related to lower product sales caused by the effects on the distributor base from product issues experienced with the medical testing machine and its effect on nutritional sales.

For the six months ended June 30, 2025, the Company paid out distributors' incentives of $11,265 and other selling, general and administrative expenses of $1,047,095 resulting in total operating expenses of $1,058,360. These selling, general and administrative expenses consisted primarily of employee expenses of $231,349 and other operating expenses of $815,746. Other operating expenses consisted of advertising and marketing of $45,567, depreciation expense of $24,754, software costs of $3,879, bank and payment charges of $3,202, contract labor of $56,140, legal and accounting of $235,610, professional services of $252,841, which includes $173,106 of fair value of grants of common shares, insurance of $20,420, taxes and licenses of $6,125, rent & lease of $27,176 and miscellaneous expenses of $140,032. Additionally, the Company had interest expense and financial costs of $145,325 resulting in net loss of $(445,199) for the six months ended June 30, 2025.

Comparatively, For the six months ended June 30, 2024, the Company paid out distributors' incentives of $167,246 and had selling, general and administrative expenses of $4,806,023 resulting in total operating expenses of $4,973,269. These selling, general and administrative expenses consisted primarily of employee expenses of $1,723,587, amortization expense of $1,059,860 and operating expenses of $2,022,576. Operating expenses consisted of advertising and marketing of $28,079, software costs of $35,809, bank and payment charges of $36,448, contract labor of $106,605, legal and accounting of $273,003, professional services of $1,395,737, insurance of $40,516, taxes and licenses of $12,767, postage of $8,519, rent & lease of $20,221, travel of $4,723 and miscellaneous expenses of $60,150. Additionally, the Company had interest expense and financial costs of $139,353 resulting in net loss of $(4,258,586) for the six months ended June 30, 2024.

Distributor incentives decreased by 93% for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 as a result of the reduction in distributor sales between the periods. Selling, general and administrative expenses decreased by 78% for the six months ended June 30, 2025 compared to the six months ended June 30, 2024, relating primarily to the decrease in equity compensation and amortization recorded during the six months ended June 30, 2025.

The Company had a loss from operations of $(299,874) and $(4,119,233) for the six months ended June 30, 2025 and June 30, 2024, respectively. For those same periods, the Company had interest expense and financing costs of $145,325 and $139,353. As a result, the Company had a net loss of $(455,199) and $(4,258,586) for the six months ended June 30, 2025 and June 30, 2024, respectively. Net loss decreased by 90% and interest expense increased by 4% for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. The resulting decreases related to decreases in net sales related to the product issues experienced with the medical testing machine and its effect on nutritional sales which were offset by decreased in equity compensation, legal, accounting, professional and amortization expenses. Interest expense increased due to higher debt balances during the six months ended June 30, 2025 compared to the six months ended June 30, 2024.

<u>Liquidity and Capital Resources</u>

Going Concern

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates the continuation of the Company as a going concern.

The Company has generated recurring losses from operations and cash flow deficits from its operations since inception and has had to raise funds through equity offerings or borrowings to continue operating. These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the six months ended June 30, 2025, the Company incurred a net loss of $445,199 and had a Stockholders' deficit of $3,654,708 as of that date. At June 30, 2025, the Company had cash on hand in the amount of $46,456. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2024, has also expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern.

The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.

Operating Activities.

For the six months ended June 30, 2025, the Company had net loss of $(455,199) and had net cash provided by operating activities of $40,900. Comparatively, for the six months ended June 30, 2024, the Company had net loss of $(4,258,586) and had net cash used in operating activities of $(281,591).The improvement in cash from operations related to efforts of management to reduce expenses and conserving cash by managing aging schedules and using equity compensation.

Investing Activities.

For the six months ended June 30, 2025, the Company invested $50,000 in its acquisition of license rights.

For the six months ended June 30, 2024, the Company made purchases of property and equipment of $(189,390), cash acquired in the DocSun transaction of $1,445 and acquired intangibles of $(2,652). As a result, the Company had net cash used in investing activities of $(190,597) for the six months ended June 30, 2024.

Financing Activities.

For the six months ended June 30, 2025, the Company made note and loan payments of $(23,592) and raised funds through notes payable amounting to $30,000. As a result, the Company had net cash provided by financing activities of $6,408.

For the six months ended June 30, 2024, the Company made note and loan payments of $(29,458), had an increase in note and loan balances of $400,000 and had an increase in note and loan balances – related parties of $32,079. As a result, the Company had net cash provided by financing activities of $402,621 for the six months ended June 30, 2024.

Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital. However, there is no assurance that such financing plans will be successful or be obtained in amounts sufficient to meet the Company's needs.

Notwithstanding, the Company anticipates generating losses and therefore may be unable to continue operations in the future. The Company anticipates it will require additional capital in order to develop its business. The Company may use a combination of equity and/or debt instruments or enter into a strategic arrangement with a third party. Management has yet to find a solution to its funding requirements.

The Company, through certain subsidiaries, financed past activities, in part, with borrowing from private parties, Small Business Administration's Economic Injury Disaster Loans (EIDL) and related parties. Loans from unrelated parties are as follows:

---

| | | |
|:---|:---|:---|
|  | 06/30/2025 | 12/31/2024 |
| (A) Howard note - In Default | $50000 | $50000 |
| (A) Howard note - In Default | 50000 | 50000 |
| (B) Goff note - In Default | 22500 | 22500 |
| (C) Insurance notes |  | 11128 |
| (D) Alder note, net of discount | 163267 | 163644 |
| (D) Genesis Glass note, net of discount | 152912 | 165000 |
| (E) EIDL notes ($400,000 in default) | 550000 | 550000 |
| (G) Other | 161805 | 126479 |
| Total | 1150484 | 1138751 |
| Less unamortized discount | (620) | (874) |
| Less current portion | (970117) | (883271) |
| Total long term | $179747 | $254606 |

---

(A) The first Howard note was advanced on 06/28/2016 and the second on 04/03/2017 to Microvascular Health Solutions, LLC. Both notes had one-year terms and both notes are in default. The stated interest rate on each note was 2.5% per month, upon default the interest rate increased to 3.5% per month. The notes are secured by the accounts receivable of the borrower. At year end after the default each note contained a provision entitling the lender to 5% ownership in the borrower, a consolidated subsidiary. The Company estimates that if the interest in the subsidiary were converted into its common shares it would represent an equivalent of 29,400,000 common shares, which would only be issuable in lieu of the interest in the subsidiary, if agreed upon by the Company.

(B) The Goff note had a maturity date of February 13<sup>th</sup>, 2016 and is in default. The original note advanced $15,000 and called for a payment of $22,500 on the maturity date. The note provides for a 4% interest rate per annum after the maturity date.

(C) Insurance notes are from finance companies that provided short term financing of insurance premiums. The notes require ten installments and were paid off as of June 30, 2025.

(D) On January 10<sup>th</sup>, 2024, the Company issued two unsecured notes for $165,000 each, Alder and Genesis Glass. The notes are due in twelve months from the note date or before if the Company brings in equity equal to $1,500,000. The funds were designated for the improvement of the technical infrastructure of the newly acquired DocSun Biomedical Holdings, Inc. Each note was issued with a $15,000 original issue discount and the issuance of 72,000 common shares with a fair value of $9,990 were paid to each lender as an additional loan fee, resulting in an aggregate loan discount of $49,980 which was amortized over the initial life of the loan. Subsequent to year end the loans were extended until October 9<sup>th</sup>, 2025 by agreement with the lender. The extension terms call for 1% interest per month and $5,000 payments per month on the Genesis Glass note until May 2025 at which time the payments become $5,000 per month for each note. The Company has issue 250,000 common shares to the lender for each note extended. In the event of default, the Company will issue the lender 3,000,000 shares of its common stock and the monthly interest rate increases to 1.5%.

---

| | |
|:---|:---|
| (E) | As of December 31, 2023, the Company had two outstanding economic injury disaster loans (EIDL loan) issued under the Small Business Administration's COVID-19 recovery program of $200,000 and $150,000. During 2024, the Company assumed another EIDL loan in the amount of $200,000 upon the acquisition of Findit, Inc. (see Note 5) resulting in total balance due as of June 30, 2025 and December 31, 2024 of $550,000. The EIDL loans are secured by the Company's assets. Each loan has a 30-year term and an interest rate of 3.75% per annum. The SBA granted a total of thirty months payment deferment period under the EIDL program for Covid-19 related loans, all of the EIDL loans qualified for and used the full deferment period. Interest continued to accrue during the deferment period and the deferred amounts will be paid as a balloon payment at the end of the 30-year amortization period. Current payments are being applied against interest accrued. The notes maturity dates are May 17, 2050 for a $150,000 note, July 12, 2051 for a $200,000 note and July 17, 2050 for the $200,000 Findit EIDL loan. |
|  | As of June 30, 2025, the Company was delinquent on payments on two of the EIDL loans in the aggregate amount of $400,000, and such amounts have been reflected as current in the accompanying financial statements. |
| (F) | As of June 30, 2025 and December 31, 2024, four and five notes including accrued interest in aggregate amounts of $181,436 and $140,621, respectively, were due. A total of 65,000 warrants with a fair value of $1,284 were issued in relation to the note proceeds and were recorded as a valuation discount to be amortized over the life of the note (of which $620 remains to be amortized at June 30, 2025). The convertible notes have a stated interest rate of 16%, of which 10% is payable by adding to the principal of the note and 6% is payable in cash, biannually. The notes are convertible into common shares at the option of the noteholder at 0.09 cents per common share. The notes mature 2 years after the note date. The Company has the option to convert the convertible notes in the event of an uplist to a national stock exchange. The conversion price to the Company is the lessor of 0.09 cents or 85% of the price at on the national exchange. For each $5,000 principal of the notes, the Company granted 2,500 warrants to purchase common stock at 0.20 cents per common share. The warrants expire 2 years after the Company's shares are listed on an internationally recognized exchange. The amounts recorded are net of unamortized discounts of $620 consisting of the fair value of the warrants granted. A total of $10,806 interest is included in the loan balances. |

---

*Related Party Loans*

BioRegenx and its subsidiaries have financed past activities, in part, with unsecured borrowings from certain related parties. Each of the listed loans below indicated with an A are demand loans that have a one-year term and an auto renewal feature. They bear interest rates from 8% to 16% per annum. The loan indicated with a B does not have stated terms. See note 10 for description of security.

The principal amount of debt from related parties is summarized in the following table:

---

| | | |
|:---|:---|:---|
| <u>Related Party</u> | 06/30/2025 | 12/31/2024 |
| &nbsp;&nbsp;&nbsp;Libertas Trust | $180000 | $180000 A |
| &nbsp;&nbsp;&nbsp;Wilshire Holding Trust | 518000 | 518000 A |
| &nbsp;&nbsp;&nbsp;Resco Enterprises Trust | 157747 | 157747 A |
| &nbsp;&nbsp;&nbsp;Avis Trust | 67606 | 67606 A |
| &nbsp;&nbsp;&nbsp;JS Bird | 32079 | 32079 A |
| &nbsp;&nbsp;&nbsp;Thomas Power | 32591 | 31093 A |
| &nbsp;&nbsp;&nbsp;Richard Long | 39862 | 39862 |
|  | $1027885 | $1026387 |

---

The entire balance of related party loans is recorded as current liabilities.

Total accrued interest on related party debts was $495,676 at June 30, 2025 and $424,277 at December 31, 2024.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Not required for a smaller reporting company.

**Item 4. Controls and Procedures**

<u>Disclosure Controls and Procedures</u>

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures. Our management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management's control objectives.

Our management, with the participation of our CEO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period ended June 30, 2025. Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not effective because of the identification material weaknesses in our internal control over financial reporting as set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Ineffective Control Environment.* The Company did not maintain an effective control environment, which is the foundation necessary for effective internal control over financial reporting. Specifically, the Company (i) did not maintain a functioning independent audit committee; (ii) did not have its Board of Directors review and approve significant transactions; (iii) had an insufficient number of personnel appropriately qualified to perform control design, execution and monitoring activities; (iv) had an insufficient number of personnel with an appropriate level of U.S. GAAP knowledge and experience and ongoing training in the application of U.S. GAAP and SEC disclosure requirements commensurate with the Company's financial reporting requirements; (v) had inadequate segregation of duties consistent with control objectives; and (vi) lack of written documentation of the Company's key internal control policies and procedures over financial reporting. The Company is required under Section 404 of the Sarbanes-Oxley Act to have written documentation of key internal control over financial reporting. The Company did not formally document policies and controls to enable management and other personnel to understand and carry out their internal control responsibilities including the lack of closing checklists, budget-to-actual analyses, balance sheet variation analysis, and pro-forma financial statements. Additionally, the Company did not have an adequate process in place to complete its testing and assessment of the design and operating effectiveness of internal control over financial reporting in a timely manner;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Ineffective controls over financial statement close and reporting process.* The Company did not maintain effective controls over its financial statement close and reporting process. Specifically, the Company: (i) had insufficient preparation and review procedures for disclosures accompanying the Company's financial statements; and (ii) did not provide reasonable assurance that accounts were complete and accurate and agreed to detailed support and that reconciliations of accounts were properly performed, reviewed and approved; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Insufficient segregation of duties in our finance and accounting functions due to limited personnel.* We do not have sufficient segregation of duties within accounting functions. During the period ended June 30, 2025, we had limited personnel that performed nearly all aspects of our financial reporting process, including, but not limited to, access to the underlying accounting records and systems, the ability to post and record journal entries and responsibility for the preparation of the financial statements. Due to the fact that these duties were often performed by the same person, this creates a lack of review over the financial reporting process that would likely result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. These control deficiencies could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

As of the date of this report, our remediation efforts continue related to each of the material weaknesses that we have identified in our internal control over financial reporting, and additional time and resources will be required in order to fully address these material weaknesses. We have not been able to complete all actions necessary and test the remediated controls in a manner that would enable us to conclude that such controls are effective. We are committed to implementing the necessary controls to remediate the material weaknesses described below as our resources permit. These material weaknesses will not be considered remediated until (1) the new processes are designed, appropriately controlled and implemented for a sufficient period of time and (2) we have sufficient evidence that the new processes and related controls are operating effectively.

<u>Changes in Internal Control Over Financial Reporting</u>

During the quarter ended June 30, 2025, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

For a description of our legal proceedings, please see Note 8 "*Commitments and Contingencies – Company Disputes and Other Claims* in the Notes to Condensed Consolidated Financial Statements set forth in Part I, Item 1 Financial Statements of this Quarterly Report.

**Item 1A. Risk Factors**

Not required for smaller reporting companies.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

During the period ended June 30, 2025, 1,936,000 common shares issuable at December 31, 2024 with an aggregate fair value of $268,620 were issued.

During the period ended June 30, 2025, the Company issued 577,479 common shares to consultants and professionals for services with an aggregate fair value of $10,663.

During the period ended June 30, 2025 the Company granted 571,430 shares of its common stock with an aggregate fair value of $11,173 to its directors and an officer for services.

During the period ended June 30, 2025 the Company issued 577,143 shares of its restricted common stock valued at $7,715 to a consultant as payment for amounts payable under a services agreement.

In the six months ended June 30, 2025, the Company granted 500,000 shares of restricted common stock valued at $5,900 to two note holders as a loan fee.

The foregoing securities were issued pursuant to exemption under 4(a)(2) of the Securities Act of 1933, as amended on the basis that there was no public offering and the Company's pre-existing relationship with each of the recipients.

**Item 3. Defaults Upon Senior Securities**

Notes payable of $522,500 are in default.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

On May 5, 2025, the Company entered into a sub-license and purchase agreement with the owners of certain intangible technology and distribution license on which the GlycoCheck systems are based. The sub-license and royalty period applies retroactively to November of 2023. The agreement calls for a royalty of $500 for each GlycoCheck system sold. The contract calls for an unconditional minimum of $750,000 in royalties over the three-year sub-license term.

There have been no changes to the procedures by which security holders may recommend nominees to the Company's board of directors.

During the quarter ended June 30, 2025, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 6. Exhibits**

The following is a list of the exhibits filed as part of this Form 10-Q. The documents incorporated by reference can be viewed on the SEC's website at http://www.sec.gov.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 3.1 | [Articles of Incorporation dated December 23, 1998](https://www.sec.gov/Archives/edgar/data/1593184/000159318421000004/ex31articles.htm) (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 filed on as filed March 11, 2021) |
| 3.2 | [Amendment to Certificate of Designation of Series B Convertible Preferred Stock filed December 30, 2015](https://www.sec.gov/Archives/edgar/data/1593184/000168316823002125/findit_ex0303.htm) (incorporated by reference to Exhibit 3.3 to Annual Report on Form 10-K, as filed on April 4, 2023) |
| 3.3 | [Certificate of Amendment to Articles of Incorporation filed with the State of Nevada on March 29, 2016](https://www.sec.gov/Archives/edgar/data/1593184/000168316823002125/findit_ex0304.htm) (incorporated by reference to Exhibit 3.4 to Annual Report on Form 10-K as filed on April 4, 2023) |
| 3.4 | [Certificate of Amendment to Articles of Incorporation filed on March 8, 2024](https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_ex0306.htm) (incorporated by reference to Exhibit 3.6 to Current Report on Form 8-K dated March 8, 2024, as filed April 1, 2024) |
| 3.5 | [Articles of Merger dated March 8, 2024](https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_ex0305.htm) (incorporated by reference to Exhibit 3.5 to Current Report on Form 8-K dated March 8, 2024, as filed on April 1, 2024) |
| 3.6 | [Certificate of Designation of Series A Preferred Shares filed March 14, 2024](https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_ex0307.htm) (incorporated by reference to Exhibit 3.7 to Current Report on Form 8-K dated March 8, 2024, as filed on April 1, 2024) |
| 3.7 | [Certificate of Correction dated March 26, 2024](https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_ex0308.htm) (incorporated by reference to Exhibit 3.8 to Current Report on Form 8-K dated March 8, 2024, as filed on April 1, 2024) |
| 3.8 | [Bylaws](https://www.sec.gov/Archives/edgar/data/1593184/000159318421000004/ex32bylaws.htm) (incorporated by reference to Exhibit 3.2 to Registration Statement on Form S-1 filed on as filed March 11, 2021) |
| 10.1\* | [Sublicense and Assignment Agreement dated May 5, 2025](bioregenx_ex1001.htm) |
| 31 | [Certification of our Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](bioregenx_ex3100.htm) |
| 32\*\* | [Certification of our Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](bioregenx_ex3200.htm) |
| 101 | The following materials from BioRegenx, Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Statements of Changes in Stockholders (Deficit), (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements |
| 104 | The cover page from the BioRegenx, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL and contained in Exhibit 101 |

---

\*Certain portions of this exhibit have been omitted because they are not material and are the type that the registrant treats as private or confidential.

\*\*These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioRegenx Inc.

<u>/s/ William Resides</u>

By: William Resides

Chief Executive Officer, Interim Chief Financial Officer

(Principal Executive Officer, Principal Financial and Accounting Officer)

Date: August 14, 2025

## Exhibit 10.1

**Exhibit 10.1**

**SUBLICENSE AND ASSIGNMENT AGREEMENT**

**Dated 5 May 2025**

**This Agreement is made between**

**1.** **Universiteit Maastricht**, a public-law entity incorporated under the laws of the Netherlands and registered
 with the Commercial Register under number 50169181, with statutory seat in Maastricht, the
 Netherlands and place of business at Minderbroedersberg 4, 6211 LK Maastricht, the Netherlands
 ()"**UM** ");

**2.** **Academisch Ziekenhuis Maastricht**, a public-law entity incorporated under the laws of the Netherlands
 and registered with the Commercial Register under number 14124959, with statutory seat in
 Maastricht, the Netherlands and place of business at P Debyelaan 25, 6229 HX Maastricht,
 the Netherlands ()"**AZM** ");

**3.** **Knowledge Transfer Funds B.V.**, a private company with limited liability incorporated under the
 laws of the Netherlands and registered with the Commercial Register under number 14085379,
 with statutory seat in Maastricht, the Netherlands and place of business at Oxfordlaan 70,
 6229 EV Maastricht, the Netherlands ()"**KTF** ");

**4.** **BioRegenX Inc.**, a company incorporated under the laws of the State of Nevada, United States of
 America, with an address of 7407 Ziegler Rd., Chattanooga, TN 37421, United States of America
 ()"**BR** ");

and

**5.** **Microvascular Health Solutions LLC**, a company incorporated under the laws of the State of Delaware, United States of America, with an address of
7407 Ziegler Road, Chattanooga, TN 37421, United States of America ()"**MVHS** ")

UM and AZM hereinafter collectively also referred to as "**Assignor**", and UM, AZM, KTF, BR, and MVHS hereinafter collectively also referred to as the "**Parties**" and individually as a "**Party**".

**Whereas**

A. UM
 and AZM are the legal owners of a certain patent relating to diagnostic and therapeutic tools
 for diseases altering vascular function (the "**IP** ", as specified in Article 1 below).

B. UM
 and AZM are the shareholders of KTF, and have granted a license with the right to sublicense
 to KTF for the IP by license agreement dated 1 August 2010 (the "**Basic License** "),
 as well as a power of attorney to conduct negotiations on behalf of UM and AZM with regard
 to the (sub)licensing and assignment of the IP.

C. KTF
holds 73.3% of the shares in GlycoCheck B.V. ()"**Glycocheck** "), a company that was originally established to focus on cardiovascular
health effect diagnosis and monitoring, and was granted a sublicense for the IP by KTF by license agreement dated 1 August 2010 (the
" **Glycocheck License Agreement** ").

D. BR is engaged in regenerative biotherapeutics,
 anti-aging, artificial intelligence for healthcare and bioinformatics for public and private
 transporation, and its primary focus involves acquiring or developing non-invase medical
 and wellness devices capable of efficiently recording, storing and analyzing extensive datasets,
 and a 100% shareholder of MVHS.

E. Since
 mid 2021, Glycocheck, BR, and MVHS were cooperating in respect of (inter alia) the sublicense
 to the IP following from the Glycocheck License Agreement and the sale of Glycocheck Systems
 (as defined in Article 1 below), pursuant to which cooperation it was MVHS that was paying
 for/ compensating the IP related costs to KTF, paying the management fees of the directors
 of Glycocheck, investing (supported by BR) in the broad development of the related technology,
 hardware (camera devices) and software for the Glycocheck Systems (as defined in Article
 1 below), and was making tremendous efforts in marketing and selling the Glycocheck Systems
 to the market.

F. Due to
 a conflict with Glycocheck and, specifically, its directors, inter alia on unpaid patent
 costs and royalties, the fact that the directors started competing activities without approval
 from Glycocheck's shareholders, and the fact that Glycocheck terminated the cooperation with
 BR and MVHS, KTF terminated the Glycocheck License Agreement by written notice of 10 November
 2023.

G. Per the same date KTF granted to MVHS
 an interim royalty-bearing exclusive sublicense to use the IP to research, develop, make,
 have made, use, import, sell and have sold, Products (as defined in Article 1 below) (the
 "**Interim Sublicense** "), to continue the cooperation with MVHS and BR, as
 the parties that were already factually responsible for the exploitation of the IP.

H. MVHS always
 wished and still wishes to continue to use the IP and BR subsequently wishes to acquire the
 IP and UM and AZM are willing to exclusively sublicense (through KTF) the IP to MVHS and,
 subsequently, assign the IP to BR.

I. To this
 effect, KTF (also on behalf of UM and AZM) and BR entered into a non-binding termsheet dated
 14 November 2024 (the "**Term Sheet** "), agreeing (inter alia) on the terms
 and conditions for an exclusive sublicense of the IP to MVHS and, subsequently, assignment
 of the IP to BR.

J. Pursuant to the Term Sheet, KTF (also on behalf of UM and AZM), BR
 and MVHS negotiated and reached agreement on the definitive terms and conditions of the exclusive sublicense of the
 IP to MVHS and assignment of the IP to BR, as set forth in this agreement (the "Agreement").

**The Parties have agreed as follows**

**Article 1 Definitions**

1.1 In this Agreement, unless otherwise clearly and unequivocally indicated by the context, the following
terms shall have the meaning set forth in this Article:

---

| | |
|:---|:---|
| **Affiliate** | an entity that, directly or indirectly, controls or is controlled by a Party; |
| **Assignor** | UM and AZM jointly; |

---

---

| | |
|:---|:---|
| **AZM** | Academisch Ziekenhuis Maastricht, as further described in the preamble; |
| **Agreement** | has the meaning as set forth in recital J; |
| **Assignment Effective Date** | has the meaning as set forth in Article 10.4; |

---

---

| | |
|:---|:---|
| **Basic License** | has the meaning as set forth in recital B; |
| **BR** | BioRegenX Inc., as further described in the preamble; |
| **BR Background IP** | the Glycocheck Trademark and all other intellectual property controlled by BR that is necessary or useful to permit the Glycocheck System to operate and was made, invented, developed, created, conceived, reduced to practice, or have a filing date before the date of this Agreement or were acquired during the term of this Agreement, other than by expressly authorized joint acquisition or ownership. This includes, with respect to each of the foregoing items, all rights in any patents or patent applications, copyrights, trade secret rights, and other intellectual property rights relating thereto (including without limitation rights in and to ongoing improvements thereof). This furthermore includes software and any other intellectual property developed by or for MVHS that is intended for use with the Glycocheck System. For purposes of this definition only, "controlled by" means, with respect to any intellectual property, the possession of (whether by ownership or license, other than pursuant to this Agreement) or the ability of a party or its affiliates to grant access, a license, or a sublicense to such intellectual property. |
| **Confidential Information** | has the meaning as set forth in Article 14.1; |
| **Continuing Royalties** | has the meaning as set forth in Article 7.6; |
| **Glycocheck** | Glycocheck B.V.; |
| **Glycocheck Dispute** | the dispute between UM, AZM and KTF on the one hand, and (inter alia) Glycocheck, Glycocheck US LLC, Mr. Bob Long, Mr. Hans Vink, Lone Peak and/or Hans Vink Beheer B.V. on the other hand, regarding (inter alia) the termination of the Glycocheck License Agreement, the rights to the IP, the compensation for the IP costs and the payment of the Receivables |
| **Glycocheck License Agreement** | has the meaning as set forth in recital C; |
| **Glycocheck System** | a system with Patented Software and Patented Hardware that can be used by healthcare professionals to identify and monitor the contribution of microvascular dysfunction and glycocalyx damage during disease development; |
| **Glycocheck Trademark** | The United States trademark registration for 'Glycocheck' in the with registration number 7694222, in the name of BR; |
| **Interim Sublicense** | has the meaning as set forth in recital G; |
| **Interim Sublicense Term** | has the meaning as set forth in Article 2.3; |

---

---

| | |
|:---|:---|
| **IP** | the Patents and any and all additional patents, trademarks, trade secrets, and related intellectual property assets, together with all related know-how, good will, and moral rights, that are relevant to the use of the Patents as set out in this Agreement, including but not limited to the Patent's underlying technology, process, and components, without any limitation or encumbrance, but not including BR Background IP; |

---

---

| | |
|:---|:---|
| **KTF** | Knowledge Transfer Funds B.V., as further described in the preamble; |
| **Lone Peak** | Lone Peak Innovative Holdings LLC; |
| **Minimum Royalties** | has the meaning as set forth in Article 7.5; |
| **MVHS** | Microvascular Health Solutions LLC, as further described in the preamble; |
| **Party** | any party to this Agreement; |
| **Patented Software** | software used in the Glycocheck System and developed using the Patents; |
| **Patented Hardware** | hardware used for the Glycocheck System and developed using the Patents; |

---

---

| | |
|:---|:---|
| **Patents** | any and all of the patents referred to in Annex 1, including any continuations, continuations in part, extensions, reissues, divisions, and any patents, supplementary protection certificates, and similar rights that derive priority from the foregoing; |
| **Prepaid Royalties** | has the meaning as set forth in Article 7.4; |

---

---

| | |
|:---|:---|
| **Product** | the Glycocheck System and any other product and/or working method that is protected by the Patents and/or IP; |
| **Purchase Price** | has the meaning as set forth in Article 10.2; |
| **Receivables** | has the meaning as set forth in Article 9.1; |
| **Related Retained IP** | has the meaning as set forth in Article 2.7; |
| **Research License** | has the meaning as set forth in Article 2.6; |
| **Royalties** | has the meaning as set forth in Article 7.1; |
| **Shares** | has the meaning as set forth in Article 10.2; |
| **Sublicense** | has the meaning as set forth in Article 2.1; |
| **Sublicense Term** | has the meaning as set forth in Article 2.2; |

---

---

| | |
|:---|:---|
| **Term Sheet** | has the meaning as set forth in recital I; |
| **UM** | Universiteit Maastricht, as further described in the preamble |

---

**Article 2 Sublicenses**

2.1 KTF grants to MVHS
and MVHS hereby accepts from KTF an exclusive, royalty-bearing, non-transfereable and non-pledgeable,
world-wide sublicense, with the right to sub-sublicense, to use the IP to research, develop, make, have made, use, import, sell and have
sold, Products (the "**Sublicense** ").

2.2 The Sublicense will be granted for three years from the date of this Agreement (the "**Sublicense Term** "),
and will terminate upon the earlier of (a) the expiry of the Sublicense Term or (b) the Assignment Effective Date.

2.3 From 10
November 2023 until the date of this Agreement (the "**Interim Sublicense Term** "), MVHS has been using
the IP to research, develop, make, use, import and sell Products prior to this Agreement, pursuant to the Interim Sublicense as
agreed between MVHS and KTF. Insofar as necessary and for the avoidance of doubt, KTF hereby confirms that MVHS was allowed to do so
on the basis of the Interim Sublicense. Parties agree that the Interim Sublicense terminates per the date of this Agreement.

2.4 MVHS
is entitled to sub-sublicense its rights under this Agreement. In the event MVHS is willing to sub-sublicense its rights under this Agreement,
MVHS shall notify KTF for what term and to whom the sub-sublicense will be granted. MVHS shall ensure that it imposes the same obligations
on its sub-sublicensees as the obligations that are imposed on MVHS in accordance with this Agreement.

2.5 In
the event that MVHS sub-sublicenses its rights under this Agreement, MVHS shall not be relieved
of any of its liabilities or obligations under this Agreement and MVHS shall be liable to KTF for all the acts, defaults and
neglects of any sub-sublicensee as if these were acts, defaults or neglects of MVHS.

2.6 UM
and AZM want to use the IP for research and educational purposes. To this effect, until the Assignment Effective Date UM and AZM each
retain the right to use the IP for research and educational purposes and upon the Assignment Effective Date, BR and MVHS will automatically,
without any further action by any Party, grant to UM and AZM each a nonexclusive, freely revokable, non-transfereable, non-pledgeable
and non-sublicensable license to use the IP. UM and AZM shall use the IP solely for research and educational purposes (the "**Research License** ").

2.7 Any intellectual property right, including but not limited to patents, trademarks, trade secrets, and related intellectual
property assets, together with all related know-how, good will, and more rights, that arises from or is related to the Research License
(the "**Related Retained IP**") shall automatically be assigned from UM and/or AZM to BR without any further action by
any Party and shall be deemed to be IP and incorporated into and subject to the terms of this Agreement.

2.8 If
UM and/or AZM desires to publish a publication that incorporates, references, or otherwise uses the Related Retained IP, it will notify
MVHS prior to such publication.

**Article 3 Representations and Warranties**

3.1 UM, AZM and KTF (as applicable) represent and warrant that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· they
 are duly organized, validly existing, and in good standing under the laws of the jurisdiction
 of their organization, and they have all requisite legal and corporate power and authority
 to execute and deliver this Agreement and to consummate the transactions contemplated thereby;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· when
 executed and delivered, this Agreement will constitute a legal, valid and binding obligation,
 enforceable against UM, AZM and/or KTF, and that the transactions contemplated by this Agreement,
 including but not limited to the Assignment, will not violate or contravene any agreement
 or require the consent of, or any agreement with a third party and will not violate any Law
 or Governmental Order or require the consent of a Governmental Authority;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· they
 have the sole and exclusive right, free and clear of any liens, claims, charges or other
 encumbrances, to grant BR and MVHS the rights to and in the IP, except for the Glycocheck
 Dispute, as disclosed to BR and MVHS;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· valid
 and enforceable written assignments have been obtained from all personnel, including employees
 and students who have contributed to the Patents, along with all inventors named in the patent
 applications, assigning all of their right, title and interest in and to the IP by law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· each
 of UM, AZM and KTF has not, and will not permit another of them to, execute any agreement
 that would materially restrict or conflict with the rights granted to BR and MVHS under this
 Agreement.

3.2 UM and AZM furthermore represent and warrant that they own the entire right, title, and interest in and
to the IP.

3.3 UM, AZM and KTF do not give any representations or warranties with regard to the workings or the potential
use of the IP. The IP is provided without any warranty of merchantability or fitness for a particular purpose, express or implied. The
entire risk of the exploitation of the IP is assumed by BR and MVHS.

3.4 BR and MVHS (as applicable) represent and warrant that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· they
 are duly organized, validly existing, and in good standing under the laws of the jurisdiction
 of its organization, and they have all the requisite legal and corporate power and authority
 to execute and deliver this Agreement and to consummate the transactions contemplated thereby;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· when
 executed and delivered, this Agreement will constitute a legal, valid and binding obligation,
 enforceable against BR and MVHS, and that the transactions contemplated by this Agreement,
 including but not limited to the Assignment and the payment of the Purchase Price by granting
 shares pursuant to Article 10.2, will not violate or contravene any agreement or require
 the consent of, or any agreement with a third party and will not violate any Law or Governmental
 Order or require the consent of a Governmental Authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· BR
 is a public company, listed in the United States of America, and in full compliance with
 all requirements rules and regulations of the Securities and Exchange Commission (SEC).

**Article 4 Glycocheck**

4.1 Glycocheck's board of directors consists of Lone Peak and Mr Hans Vink. KTF will endeavour to remove Lone
Peak and Mr. Vink from the Glycocheck's board of directors as soon as reasonably practicable after the date of this Agreement.

4.2 As mentioned in Recital F above, KTF terminated the Glycocheck License Agreement per 10 November 2023.
Glycocheck contested the termination. KTF reviewed Glycocheck's claims and is convinced that they are not valid. KTF, UM and AZM can
however not guarantee the outcome of the Glycocheck Dispute, and BR and MVHS acknowledge this.

4.3 From the Assignment Effective Date, any disputes regarding the termination of the Glycocheck License Agreement
will be handled by BR and/or MVHS. KTF, UM and AZM will provide BR and/or MVHS with full cooperation in connection with any such future
disputes, including but not limited to by providing access to its attorneys' notes and opinions regarding the validity of the termination
of the Glycocheck License Agreement and Glycocheck's challenges thereto.

**Article 5 Obligations BR and MVHS**

5.1 BR and MVHS recognize and acknowledge that, until the Assignment Effective Date, UM and AZM are the sole
owners of the IP.

5.2 Until the Assignment Effective Date, BR and MVHS agree to safeguard and uphold the reputation and prestige
of the IP and shall avoid tarnishing the image of or adversely impacting the value, reputation or goodwill associated with the IP. For
the sake of clarity, any threatened or actual litigation or collections efforts that relate to the Glycocheck Dispute or the Receivables
are permissible.

5.3 Until the Assignment Effective Date, BR and MVHS agree to not represent, sell, promote or manufacture,
directly or indirectly, any products that compete with the Product.

5.4 Until the Assignment Effective Date, BR and MVHS shall not use the IP in any other way than permitted
in this Agreement, and agree that in using the IP, they will in no way imply that they have any right, title or interest in IP other
than those expressly granted under the terms of this Agreement. BR and MVHS further agree that until the Assignment Effective Date, they
will not use or attempt to register, any trademark or patents consisting of or containing the IP or any other patent, trademark, trade
name or other designation similar, in whole or in part, to the IP, unless with prior written permission from KTF.

**Article 6 Enforcement**

6.1 Each Party shall promptly notify the other Party or Parties (as applicable) in writing of any actual or
suspected infringement or misappropriation of the IP or any declaratory judgment filing with respect to the Patents. BR and/or MVHS and
any sublicensee of MVHS have the first right, in BR's and/or MVHS's discretion, to bring any action or proceeding with respect to such
infringement or misappropriation and to control its conduct (including any settlement). Any damages, profits, and other monetary awards
resulting from any such action or proceeding will be retained in their entirety by BR and/or MVHS or its designated sublicensee.

6.2 Unless such legal action, infringement or illegal use is already known to KTF per the date of this Agreement,
BR and/or MVHS agree to immediately notify KTF in writing in the event (i) any legal action is taken against BR and/or MVHS related to
the use of the IP, or (ii) BR and/or MVHS becomes aware of any infringement or illegal use by any third party of the IP.

6.3 Each Party shall provide the other Party or Parties (as applicable) and its sublicensees with all cooperation
and assistance that such other Party or Parties (as applicable) or its sublicensees may reasonable request in connection with such action
or proceeding, including joining as plaintiff to establish standing or if otherwise necessary to bring the action.

6.4 From the date of this Agreement, BR and MVHS are solely responsible for all actions and costs whatsoever,
including attorney's fees, arising after the date of this Agreement and associated with the continuous prosecution and maintenance and
enforcement of the IP, including but not limited to claims relating to the Glycocheck Dispute, and UM, AZM nor KTF shall have any obligation
to pay any maintenance fees and/or any other cost related to enforcement or prosecution arising after the date of this Agreement. From
the date of this Agreement, BR and/or MVHS shall indemnify UM, AZM and/or KTF against all costs and damages relating to the continuous
prosecution and maintenance and enforcement of the IP, including but not limited to the Glycocheck Dispute. UM, AZM and/or KTF remain
liable for any costs related to actions or claims not related to the Glycocheck Dispute and resulting from any action or inaction by
UM, AZM and/or KTF before the date of this Agreement.

6.5 BR and/or MVHS shall fully compensate UM, AZM and/or KTF for the annual fees for the IP for 2023 and 2024
as paid by UM, AZM and/or KTF, with a total amount of EUR 34,706.65 (Thirtyfour Thousand Seven Hundred Six Euro and Sixtyfive Eurocents)
within thirty (30) days from the date of this Agreement. KTF has already provided BR with the relevant invoices.

**Article 7 Royalties**

7.1 MVHS owes to KTF a royalty of USD 500.00 (Five Hundred United States dollars) for each Glycocheck System
sold by MVHS, its Affiliates or its sub-sublicensees during the Sublicense Term and the Interim Sublicense Term, for which payment has
been received in full (the "**Royalties** ").

7.2 Within fiveteen (15) days from the end of each calender quarter or part thereof during the Sublicense Term,
MVHS shall account for the (number of) Glycocheck Systems sold by MVHS, its Affiliates or its sub-sublicensees during such calender quarter
or part thereof, and shall provide KTF with the underlying documents. KTF has the right to verify or have verified by a certified public
accountant, the (number of) Glycocheck Systems sold by MVHS, its Affiliates or its sub-sublicensees during a calender quarter or part
thereof during the Sublicense Term or Interim Sublicense Term. The costs of this verification shall be borne by KTF unless it follows
from the undisputed verification that MVHS provided numbers that are incorrect by more than 2%. MVHS shall keep the relevant underlying
documents for at least 7 years and shall provide KTF with full access to such documents if so requested by KTF.

7.3 After having received the sales account in conformity with Article 7.2, KTF shall invoice MVHS within five
(5) days for the accrued Royalties in the respective calender quarter or part thereof. MVHS shall pay the invoice from KTF within fifteen
(15) days of the invoice date.

7.4 Within sixty (60) days from the date of this Agreement, MVHS shall make a prepayment of Royalties amounting
to USD 50,000.00 (Fifty Thousand United States Dollars) (the "**Prepaid Royalties** "). KTF shall provide MVHS with an invoice
for the Prepaid Royalties within thirty (30) days from the date of this Agreement. The Prepaid Royalties will be deducted from the Royalties
payable by MVHS over the first 100 Glycocheck Systems sold during the Sublicense Term or the Interim Sublicense Term.

7.5 MVHS agrees to pay, at a minimum, Royalties amounting to USD 750,000.00 (Seven Hundred Fifty Thousand United
States Dollars) over the Sublicense Term and the Interim Sublicense Term (the "**Minimum Royalties** "). If at the end of
the Sublicense Term, MVHS has not paid Royalties to KTF in an amount equal to or greater than the amount of the Minimum Royalties, MVHS
shall make a payment to KTF equal to the difference between the amount of Royalties paid per the end of the Sublicense Term and the amount
of the Minimum Royalties. The Minimum Royalties are a minimum only, meaning that MVHS may owe more Royalties than the Minimum Royalties
if it sells more than 1,500 Glycocheck Systems during the Sublicense Term and the Interim Sublicense Term.

7.6 If the Assignment Effective Date occurs before the end of the Sublicense Term, this will have no effect
on MVHS's obligation to pay Royalties in accordance with this Article 7, meaning that MVHS will continue to pay Royalties for the remainder
of the Sublicense Term as if the Assignment Effective Date did not occur before the end of the Sublicense Term (the "**Continuing Royalties** "), provided that the payment of any unpaid balance of Minimum Royalties pursuant to Article 10.1 will be deducted
from the Continuing Royalties payable by MVHS.

**Article 8 Guarantee**

8.1 BR irrevocably and unconditionally guarantees by way of an independent obligation to UM, AZM and/or KTF
(as applicable), the punctual performance by MVHS of all MVHS's obligations under this Agreement, including but not limited to the payment
obligations following from Article 7.

8.2 This guarantee is an independent guarantee and not a suretyship (*borgtocht*) or joint and several
debtorship (*hoofdelijkheid*). BR waives any rights it may have under title 7.14 of the Dutch Civil Code, if any.

8.3 Until all amounts which may be or become payable by MVHS under or in connection with this Agreement have
been irrevocably paid in full, BR will not, after a claim has been made or by virtue of any payment by BR under this Article 8, be entitled
to exercise a right of recourse (*regres*) or any right of subrogation (*subrogatie*).

**Article 9 Sale of Receivables**

9.1 Glycocheck owes certain amounts to UM, AZM and KTF respectively, in a total amount of approximately EUR
1,000,000.00 (One Million Euros), as specified in Annex II (the "**Receivables** ").

9.2 UM, AZM and KTF each assign to BR and BR accepts from each of UM, AZM and KTF their respective part of
the Receivables. Parties agree to do everything that might be useful, necessary and/or required to effectuate the assignment of the Receivables.

9.3 UM, AZM and KTF will each, or jointly through KTF, notify Glycocheck of the transfer of their respective
part of the Receivables to BR within thirty (30) days from the date of this Agreement.

9.4 UM, AZM and KTF represent that the Receivables are valid, due and payable and not subject to any set-off
or valid defense, and will provide BR with documentation and records concerning the Receivables, including a detailed list of Receivables,
corresponding debtor information, amounts due and any associated agreements or contracts.

**Article 10 Assignment**

10.1 At the end of the Sublicense Term or so much sooner as desired by BR, BR shall exercise its option to purchase
the IP by paying the purchase price (as defined in 10.2) and any unpaid balance of the Minimum Royalties.

10.2 The total purchase price for the IP shall be USD 1,000,000.00 (One Million United States Dollars) (the
" **Purchase Price** "). The Purchase Price shall be paid by granting Assignor and/or KTF shares in BR (the "**Shares** ")
to the value of the Purchase Price per the time of the execution of the stock purchase agreement in accordance with Article 10.3.

10.3 Parties will enter into a stock purchase agreement regarding the Shares, containing standard representations
and warranties, including but not limited to the representations and warranties given by BR in Article 3.4. The Shares will be allocated
between Assignor, KTF and/or one of its Affiliates, as directed by Assignor and KTF upon entering into the stock purchase agreement.
By accepting the Shares, Assignor, the/any party receiving the Shares will be bound by BR's corporate documents, including but not limited
to its bylaws, its articles of incorporation, and any other internal governance documents. BR will provide all such documents to the/any
party receiving the Shares.

10.4 Upon payment of the Purchase Price (i.e. the Shares being in possession
of Assignor, KTF and/or one of its Affiliates) and payment of any unpaid balance of the Minimum Royalties, the IP shall automatically
be assigned from Assignor to BR without any further action from any Party (the "**Assignment Effective Date** ").

10.5 The Parties agree to register the assignment of the IP in the relevant registers within thirty(30) days
from the Assignment Effective Date. To that end, by signing this Agreement, Assignor grants to BR power of attorney to register this
Agreement and the resulting assignment of the IP in the relevant registers within (30) days from the Assignment Effective Date.

**Article 11 Payments**

11.1 All cash payments under this Agreement are to be made in United States Dollars to the following bank account
of KTF, unless otherwise specified by KTF:

---

| | |
|:---|:---|
| Bank | : Coöperatieve Rabobank U.A. |
| Account holder | : Knowledge Transfer Funds B.V. |
| IBAN | : NL48RABO0110088565 |
| BIC | : RaboNL2U |

---

11.2 As applicable, any payments shall be translated from Euros to United Stated Dollars or vice versa using
the exchange rate published by the European Central Bank or, for any particular exchange rate not published by the European Central Bank,
published by Bloomberg, in each case on the business day immediately preceding the payment.

**Article 12 Term and termination**

12.1 This Agreement will terminate after the end of the Sublicense Term upon MVHS paying any unpaid Royalties
in accordance with Article 7 and, if applicable, BR paying the Purchase Price in accordance with Article 10.

12.2 Without prejudice to any other rights, any Party shall have the right to terminate this Agreement prior
to the Assignment Effective Date upon written notice to the other Party at any time under the following circumstances:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· if
 any other Party applies for, consents to or becomes subject to the appointment of a receiver,
 manager or administrative receiver over any of its property or assets;

· if
 any other Party goes into liquidation or an order is made or a resolution is passed for the
 winding-up of that other Party; and/or

· if
 any other Party fails to perform any material term of this Agreement and such nonperformance
 is not cured after thirty (30) days' written notice.

12.3 Without prejudice to any other rights and notwithstanding Article 12.2, BR and/or MVHS shall furthermore
have the right to terminate this Agreement prior to the Assignment Effective Date upon written notice if UM, AZM or KTF sells, grants,
authorizes, or permits a third party to sell, grant, or authorize, any right in or to the IP. In the event of a termination pursuant
to this Article 12.3, UM, AZM and/or KTF shall immediately refund all Royalties to MVHS and MVHS shall have no further obligations to
pay Minimum Royalties or Continuing Royalties.

12.4 Upon the termination of this Agreement in accordance with Article 12.2 by AZM, UM and/or KTF, all rights
of BR and MVHS under this Agreement shall terminate immediately and revert to AZM, UM and/or KTF (as applicable), and any unpaid Royalties
in accordance with Article 7 shall become immediately due and payable.

12.5 The Parties waive their rights to claim compensation by reason of the expiration or termination of this
Agreement, except where such claims are based on a breach of this Agreement by an other Party.

**Article 13 Indemnity**

13.1 BR and/or MVHS (as applicable) will indemnify UM, AZM and/or KTF and keep them indemnified against all
costs, claims, damages or expenses incurred by UM, AZM and/or KTF in relation to (i) any third-party claims arising out of or related
to any breach of this Agreement, including but not limited to any breach of any warranty or representation made by BR and/or MVHS and/or
their failure to perform any obligations under this Agreement and (ii) any claims arising out of or related to the Glycocheck Dispute,
except to the extent attributable to the negligence or wilful misconduct of UM, AZM and/or KTF.

13.2 UM, AZM and/or KTF will indemnify BR and/or MVHS (as applicable) and keep them indemnified against all
costs, claims, damages or expenses incurred by BR and/or MVHS in relation to any third-party claims arising out of or related to any
breach of this Agreement, including but not limited to any breach of any warranty or representation made by UM, AZM and/or KTF and/or
their failure to perform any obligations under this Agreement, except to the extent attributable to the negligence or wilful misconduct
of BR and/or MVHS.

13.3 If a court determines, in a final judgment, that the Glycocheck License Agreement was not terminated and
remains in full force and effect, or that Mr. Long and/or Mr. Vink (directly or through a third party) have rights in the IP that limit
BR's and/or MVHS's ability to commercially and exclusively exploit the IP, then any Party has the right to terminate this Agreement and
reverse the granting of the Sublicense, the payment of the Purchase Price and/or the Assignment of the IP, as applicable.

13.4 This Article 13 shall remain in full force after expiration or termination of this Agreement.

**Article 14 Confidentiality**

14.1 The Parties agree that the terms and conditions of this Agreement, as well as the content of all previous
discussions and documents exchanged concerning the subject and/or the performance of this Agreement, shall be confidential and neither
they nor their successors, assigns, attorneys or agents shall disclose this Agreement, parts of it or secret information contained in
it to any person or entity, except when this is required by applicable rules of civil procedure or as ordered by a court or other authority
of competent jurisdiction.

14.2 Notwithstanding Article 14.1 above, Parties agree that any Party can inform Mr. Long and/or Mr. Vink (directly
or through a third party) that the IP has been exclusively sublicensed to MVHS and is or will be assigned to BR if such Party thinks
this is helpful in relation to the Glycocheck Dispute. Furthermore, UM, AZM and KTF are allowed to notify Glycocheck of the transfer
of the Receivables pursuant to Article 9.3.

14.3 BR and MVHS undertake to, until the Assignment Effective Date, observe strict confidentiality about the
production, know-how, designs, samples, marketing plans, ideas and other related documentation and confidential information with regard
to the IP of which it takes cognizance (the "**Confidential Information** ").

14.4 UM, AZM and KTF undertake to, from the Assignment Effective Date, observe strict confidentiality about
the Confidential Information.

14.5 Confidential Information does not include information of which a Party can show that (a) it was in its
possession before it was disclosed by another Party (b) it is public knowledge (c) it has been obtained lawfully from a third party,
without infringing this Agreement, or (d) it has been developed independently by it without direct or indirect use of Confidential Information.
Additionally, Confidential Information does not include BR Background IP.

14.6 This Article 14 shall remain in full force after expiration or termination of this Agreement.

**Article 15 Miscellaneous**

15.1 Each Party shall, and shall cause their respective Affiliates to, upon the reasonable request of the other
Party, promptly execute such documents and take such further actions as may be necessary to give full effect to the terms of this Agreement.

15.2 The Parties are and intend to remain independent contractors. Nothing in this Agreement shall be construed
as an agency, joint venture or partnership between the Parties.

15.3 Parties have the intention to enter into negotiations for future R&D collaboration. If this leads to
any agreement or collaboration, specific agreements regarding new intellectual property rights will be made.

15.4 This Agreement cannot be changed, modified or amended unless such change, modification or amendment is
in writing and agreed upon by all Parties.

15.5 If any provision of this Agreement is determined to be invalid or unenforceable by a court of competent
jurisdiction, such finding shall not invalidate the remainder of this Agreement which shall remain in full force and effect as if the
provision(s) determined to be invalid or unenforceable had not been a part of this Agreement. In the event of such finding of invalidity
or unenforceability, the Parties will substitute forthwith the invalid or unenforceable provision(s) by such effective provision(s) as
most closely correspond with the original intention of the provision(s) so voided.

15.6 This Agreement contains the entire understanding and agreement between the Parties as to the subject matter
of this Agreement and supersedes, cancels and merges all prior agreements, negotiations, commitments, communications and discussions
between the Parties as to the subject matter hereof, including the Term Sheet. No Party shall be bound by any obligation, warranty, waiver,
release or representation, except as expressly provided herein, or as may subsequently be agreed by a written instrument, signed by duly
authorized representatives of all Parties.

15.7 Neither the failure nor the delay of either Party to enforce any provision of this Agreement shall constitute
a waiver of such provision or of the right of a Party to enforce each and every provision of this Agreement.

**Article 16 Applicable and jurisdiction**

16.1 This Agreement shall be governed by and construed in accordance with the laws of the Netherlands.

16.2 All disputes arising out of or in connection with this Agreement and any other agreement(s) between Parties
shall be finally settled under thev Arbitration Rules of the Netherlands Arbitration Institute by one or more arbitrators appointed in
accordance with the said rules. The place of arbitration shall be Amsterdam, the Netherlands. The proceedings shall be conducted in English.

*[signature page follows]*

**Knowledge Transfer Funds B.V.**

---

| | |
|:---|:---|
| /s/ Wim Bens | /s/ Wim Bens |
| By: | Bens & Partners BV |
|  | Represented by W.E.J.M. Bens MSc RTTP |
| Title: | CEO, KTF |
| Date: | 5/5/2025 |

---

**Universiteit Maastricht**

---

| | |
|:---|:---|
| /s/ Mr. J. Meindersma | /s/ Mr. J. Meindersma |
| By: | Mr. J. Meindersma |
| Title: | Member Executive Board UM |
| Date: | 5/6/2025 |

---

**Academisch Ziekenhuis Maastricht**

---

| | |
|:---|:---|
| /s/ Dr. G. Zwart, MAC | /s/ Dr. G. Zwart, MAC |
| By: | Dr. G. Zwart, MAC |
| Title: | Member Executive Board azM |
| Date: | 5/7/2025 |

---

**BioRegenx Inc.**

---

| | |
|:---|:---|
| /s/ William Resides | /s/ William Resides |
| By: | William Resides |
| Title: | CEO |
| Date: | 5/8/2025 |

---

**Microvascular Health Solutions LLC**

---

| | |
|:---|:---|
| /s/ Diane Bouis | /s/ Diane Bouis |
| By: | Diane Bouis |
| Title: | CEO |
| Date: | 5/7/2025 |

---

---

| | |
|:---|:---|
| **ANNEX I** | **THE PATENT** |

---

the Patent with International Publication Number WO 2009/068685 A1 "Diagnostic and therapeutic tools for diseases altering vascular function", WO2009068685A1.pdf (storage.googleapis.com)

Links to the respective patents are provided below:

PCT International Publication Number WO 2009/068685:

https://patentimages.storage.googleapis.com/00/99/03/b8739aa88db354/WO2009068685A 1.pdf

United States: 8759095B2:

https://patents.google.com/patent/US8759095B2/en?oq=8759095

Canada: CA2706307C: https://patents.google.com/patent/CA2706307C/en?oq=2706307

Europe: EP2215480B1 (Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, Norway, Poland, Portugal, Romania, Spain, Sweden, Switzerland, The Netherlands, and United Kingdom): https://patents.google.com/patent/EP2215480B1/en?oq=+EP2215480B1+

China CN101918845A:

https://patents.google.com/patent/CN101918845A/en?oq=CN101918845A

Japan JP5597543B2: https://patents.google.com/patent/JP5597543B2/en?oq=JP5597543B2

---

| | |
|:---|:---|
| **ANNEX II** | **THE RECEIVABLES** |

---

Glycocheck owes certain amounts to UM, AZM and KTF respectively, in a total amount of approximately EUR 1,000,000.00 (One Million Two Hundred Thousand Euros) (the "**Receivables**").

The total value – updated with calculated interest – per 30 April 2025 is:

---

| | | | |
|:---|:---|:---|:---|
| - Outstanding invoices UM - Carim |  | Euro | 93.655,= |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Salary cost H. Vink | 93.655 |  |  |
| - Outstanding invoices / loans / interest azM |  | Euro | 429.074,= |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loan | 250.0 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 125.394 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outstanding invoices SSC | 53.68 |  |  |
| - Outstanding invoices / loans / interest KTF |  | Euro | 505.945,= |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outstanding invoices historical patentcosts | 165.662 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loan | 100.0 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 71.468 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties until end / november 2023 | 179.001 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remaining NGI Grant to be paid by BMB/KTF | -10.186 |  |  |

---

## Ex-31

**Exhibit 31**

**Certification of our Chief Executive Officer and Interim Chief Financial Officer** 

**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, William Resides, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioRegenx, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2025

<u>/s/ William Resides</u> 

Name: William Resides <br> Titles: Chief Executive Officer, Interim Chief Financial Officer <br> (Principal Executive Officer, Principal Financial and Accounting Officer)

## Ex-32

**Exhibit 32**

**Certification of our Chief Executive Officer and Interim Chief Financial Officer** 

**Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, William Resides, the Chief Executive Officer and Interim Chief Financial Officer of BioRegenx, Inc. (the "Company"), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the "Report") of the Company fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2025

<u>/s/ William Resides</u> 

Name: William Resides <br> Titles: Chief Executive Officer, Interim Chief Financial Officer <br> (Principal Executive Officer, Principal Financial and Accounting Officer)